# EDGAR Filing Document

**Accession Number:** 0001509745
**File Stem:** 0001104659-25-110341
**Filing Date:** 2025-11
**Character Count:** 184596
**Document Hash:** 77beffbc8c5f634a170189d29da7f634
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-110341.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001104659-25-110341

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20251112

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LEAP THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001509745
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 274412575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37990
- **FILM NUMBER:** 251472659

**BUSINESS ADDRESS:**
- **STREET 1:** 47 THORNDIKE STREET
- **STREET 2:** SUITE B1-1
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617 252 4343

**MAIL ADDRESS:**
- **STREET 1:** 47 THORNDIKE STREET
- **STREET 2:** SUITE B1-1
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Dekkun Corp
- **DATE OF NAME CHANGE:** 20110107

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 12, 2025**

![](tm2530735d2_8kimg001.jpg)

**Cypherpunk Technologies Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37990** | **27-4412575** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission <br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

**47 Thorndike Street, Suite B1-1**

**Cambridge, MA** **02141**

(Address of Principal Executive Office) (Zip Code)

 **(617) 714-0360**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Title of each class** | &nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;**Name of each exchange on which registered** |
| &nbsp;&nbsp;Common Stock, par value $0.001 per share | &nbsp;&nbsp;LPTX | &nbsp;&nbsp;The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Explanatory Note**

As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2205, Leap Therapeutics, Inc. has changed its name to Cypherpunk Technologies Inc., effective on and as of November 12, 2025.

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement.** |

---

On November 12, 2025, Cypherpunk Technologies Inc. (f./k/a Leap Therapeutics, Inc.), a Delaware corporation (the "Company"), entered into a Controlled Equity Offering<sup>SM</sup> Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor"), pursuant to which the Company may offer and sell shares of its common stock, par value $0.001 per share (the "Shares"), having an aggregate offering price of up to $200,000,000 from time to time to or through Cantor, acting as principal and/or sales agent (the "Offering").

Subject to the terms and conditions of the Sales Agreement, Cantor will use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of the Nasdaq Capital Market to sell the Shares pursuant to the Offering from time to time, based upon the Company's instructions, including any price, time or size limits specified by the Company. The Company has provided Cantor with customary indemnification and contribution rights in favor of Cantor, and Cantor will be entitled to a commission of up to 3.0% of the gross proceeds from each sale of the Shares pursuant to the Sales Agreement.

Sales of the Shares, if any, under the Sales Agreement may be made in transactions that are deemed to be "at the market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended (the "Securities Act") or by any other method permitted by law. The Company has no obligation to sell any of the Shares and may at any time suspend offers under the Sales Agreement. The Company and Cantor may each terminate the Sales Agreement at any time upon ten business days prior notice.

The Shares to be sold under the Sales Agreement, if any, will be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-278015) as filed with the Securities and Exchange Commission on March 18, 2024 and declared effective May 9, 2024 (the "Registration Statement"). Offerings for the Shares will be made only by means of the prospectus supplement to the Registration Statement filed with the Securities and Exchange Commission on November 12, 2025.

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The legal opinion of Morgan, Lewis & Bockius LLP relating to the Shares being offered is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any Shares, nor shall there be any sale of Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

**9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [1.1](tm2530735d2_ex1-1.htm) | [Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated November 12, 2025, by and between the Company and Cantor Fitzgerald & Co.](tm2530735d2_ex1-1.htm) |
| [5.1](tm2530735d2_ex5-1.htm) | [Opinion of Morgan, Lewis & Bockius LLP](tm2530735d2_ex5-1.htm) |
| [23.1](tm2530735d2_ex5-1.htm) | [Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1)](tm2530735d2_ex5-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | **CYPHERPUNK TECHNOLOGIES INC.** |
| Date: November 12, 2025 | /s/ Douglas E. Onsi |
|  | Douglas E. Onsi |
|  | President & CEO |

---

## Exhibit 1.1

**Exhibit 1.1**

**CYPHERPUNK TECHNOLOGIES INC. (F/K/A LEAP THERAPEUTICS, INC.)**<br> Shares of Common Stock<br> (par value $0.001 per share)

**Controlled Equity Offering<sup>SM</sup>**

**<u>Sales Agreement</u>**

November 12, 2025

Cantor Fitzgerald & Co.<br> 499 Park Avenue<br> New York, NY 10022

Ladies and Gentlemen:

Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.), a Delaware corporation (the "**<u>Company</u>**"), confirms its agreement (this "**<u>Agreement</u>**") with Cantor Fitzgerald & Co. (the "**<u>Agent</u>**"), as follows:

1. <u>Issuance and Sale of Shares</u>. The Company agrees that, from time
 to time during the term of this Agreement, on the terms and subject to the conditions set forth herein,
 it may issue and sell to or through the Agent, as sales agent or principal, shares of common stock (the
 "  **<u>Placement Shares</u>**") of the Company, par value $0.001 per share (the "  **<u>Common Stock</u>** "); *provided*, *however*, that in no event shall the Company issue or sell
 through the Agent such number or dollar amount of Placement Shares that would (a) exceed the number
 or dollar amount of shares of Common Stock registered on the effective Registration Statement (defined
 below) pursuant to which the offering is being made, (b) exceed the number of authorized but unissued
 shares of Common Stock (less shares of Common Stock issuable upon exercise, conversion or exchange of
 any outstanding securities of the Company or otherwise reserved from the Company's authorized capital
 stock), (c) exceed the number or dollar amount of shares of Common Stock permitted to be sold under
 Form S-3 (including General Instruction I.B.6 thereof, if applicable) or (d) exceed the number
 or dollar amount of shares of Common Stock for which the Company has filed a Prospectus Supplement (defined
 below) (the lesser of (a), (b), (c) and (d), the "  **<u>Maximum Amount</u>** "). Notwithstanding
 anything to the contrary contained herein, the parties hereto agree that compliance with the limitations
 set forth in this <u>Section 1</u> on the amount of Placement Shares issued and sold under this
 Agreement shall be the sole responsibility of the Company and that the Agent shall have no obligation
 in connection with such compliance. The offer and sale of Placement Shares through the Agent will be
 effected pursuant to the Registration Statement (as defined below) filed by the Company and declared
 effective by the Securities and Exchange Commission (the "  **<u>Commission</u>**") on May 9,
 2024, although nothing in this Agreement shall be construed as requiring the Company to use the Registration
 Statement to issue Common Stock.

The Company has prepared and filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (the "**<u>Securities Act</u>** "), with the Commission a registration statement on Form S-3 (File No. 333-278015), including a base prospectus, relating to certain securities, including the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the "**<u>Exchange Act</u>**"). The Company has prepared a prospectus or prospectus supplement to the base prospectus included as part of the registration statement, which prospectus or prospectus supplement relates to the Placement Shares to be issued from time to time by the Company (the "**<u>Prospectus Supplement</u>**"). Except where the context otherwise requires, such registration statement(s), including all documents filed as part thereof or incorporated by reference therein, and including any information contained in the Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act, and any one or more additional effective registration statements on Form S-3 from time to time that will contain a base prospectus and, if applicable, a related prospectus or prospectus supplement with respect to the Placement Shares, is herein called the "**<u>Registration Statement</u>**." The base prospectus or base prospectuses, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented, if necessary, by the Prospectus Supplement, in the form in which such prospectus or prospectuses and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any then issued Issuer Free Writing Prospectus(es) (as defined below), is herein called the "**<u>Prospectus</u>**."

Any reference herein to the Registration Statement, any Prospectus Supplement, Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus shall be deemed to refer to and include the documents, if any, incorporated by reference therein (the "**<u>Incorporated Documents</u>**"), including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms "amend," "amendment" or "supplement" with respect to the Registration Statement, any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or the date of the Prospectus Supplement, Prospectus or such Issuer Free Writing Prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval system, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, "**<u>EDGAR</u>**").

All references in this Agreement to financial statements and schedules and other information that is "contained," "included" or "stated" in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be.

All references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission) shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to "supplements" to the Prospectus shall include, without limitation, any supplements, "wrappers" or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.

2. <u>Placements</u>. Each time that the Company wishes and determines in
 its sole discretion to issue and sell Placement Shares hereunder (each, a "  **<u>Placement</u>** "),
 it will notify the Agent by email notice (or other method mutually agreed to by the parties) of the number
 of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation
 on the number of Placement Shares that may be sold in any one day and any minimum price below which sales
 of Placement Shares may not be made (a "  **<u>Placement Notice</u>** "), the form of which
 is attached hereto as <u>Schedule 1</u>. The Placement Notice shall originate from any of the individuals
 authorized to act on behalf of the Company, which individuals have been identified by the Company on <u>Schedule 3</u>, and shall be addressed to each of the individuals identified by the Agent on <u>Schedule 3</u>, as such <u>Schedule 3</u> may be updated by either party from time to time by sending a written
 notice containing a revised <u>Schedule 3</u> to the other party in the manner provided in <u>Section 13</u>.
 The Placement Notice shall be effective unless and until (i) in accordance with the notice requirements
 set forth in <u>Section 4</u>, the Agent declines to accept the terms contained therein for any
 reason, in its sole discretion, (ii) all of the Placement Shares authorized to be sold under such
 Placement Notice have been sold, (iii) in accordance with the notice requirements set forth in <u>Section 4</u>,
 the Company suspends or terminates the Placement Notice for any reason in its sole discretion, or (iv) this
 Agreement has been terminated under the provisions of <u>Section 12</u>. The amount of any discount,
 commission or other compensation to be paid by the Company to the Agent in connection with the sale of
 the Placement Shares shall be calculated in accordance with the terms set forth in <u>Schedule 2</u>.
 It is expressly acknowledged and agreed that neither the Company nor the Agent will have any obligation
 whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers
 a Placement Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the
 terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict
 between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice
 will control.

3. <u>Sale of Placement Shares by the Agent</u>. Subject to the provisions
 of <u>Section 5(a)</u>, the Agent, for the period specified in the Placement Notice, will use its
 commercially reasonable efforts consistent with its normal trading and sales practices and applicable
 state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market (the
 "  **<u>Exchange</u>** "), to sell the Placement Shares up to the amount specified in, and
 otherwise in accordance with the terms of, such Placement Notice. The Agent will provide written confirmation
 to the Company no later than the opening of the Trading Day (as defined below) immediately following
 the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of
 Placement Shares sold on such day, the compensation payable by the Company to the Agent pursuant to <u>Section 2</u> with respect to such sales, and the Net Proceeds (as defined below) payable to the Company, with an itemization
 of the deductions made by the Agent (as set forth in <u>Section 5(a)</u>) from the gross proceeds
 that it receives from such sales. Subject to the terms of the Placement Notice, the Agent may sell Placement
 Shares by any method permitted by law deemed to be an "at the market offering" as defined
 in Rule 415(a)(4) of the Securities Act. "  **<u>Trading Day</u>**" means any
 day on which Common Stock is traded on the Exchange. The Company acknowledges and agrees that (i) there
 can be no assurance that the Agent will be successful in selling Placement Shares, (ii) the Agent
 will incur no liability or obligation to the Company or any other person or entity if it does not sell
 Placement Shares for any reason other than a failure by the Agent to use its commercially reasonable
 efforts consistent with its normal trading and sales practices to sell such Placement Shares as required
 under this Agreement and (iii) the Agent shall be under no obligation to purchase Placement Shares
 on a principal basis pursuant to this Agreement.

4. <u>Suspension of Sales</u>. The Company or
 the Agent may, upon notice to the other party in writing (including by email correspondence
 to each of the individuals of the other party set forth on <u>Schedule 3</u>, if receipt
 of such correspondence is actually acknowledged by any of the individuals to whom the notice
 is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable
 email correspondence to each of the individuals of the other party set forth on <u>Schedule 3</u>), suspend any sale of Placement Shares (a "  **<u>Suspension</u>** "); *provided*, *however*, that such Suspension shall not affect or impair any party's
 obligations with respect to any Placement Shares sold hereunder prior to the receipt of such
 notice. While a Suspension is in effect any obligation under <u>Sections 7(l)</u>, <u>7(m)</u>, <u>7(n)</u>, and <u>7(u)</u> with respect to the delivery of certificates, opinions,
 or comfort letters to the Agent, shall be waived. Each of the parties agrees that no such
 notice under this <u>Section 4</u> shall be effective against any other party unless
 it is made to one of the individuals identified on <u>Schedule 3</u>, as such <u>Schedule 3</u> may be updated by either party from time to time by sending a written notice containing
 a revised <u>Schedule 3</u> to the other party in the manner provided in <u>Section 13</u>.
 Notwithstanding any other provision of this Agreement, during any period in which the Company
 is in possession of material non-public information, the Company and the Agent agree that
 (i) no sale of Placement Shares will take place, (ii) the Company shall not request
 the sale of any Placement Shares and shall cancel any effective Placement Notices instructing
 the Agent to make any sales, and (iii) the Agent shall not be obligated to sell or offer
 to sell any Placement Shares.

5. <u>Settlement; Delivery to the Agent</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Settlement of Placement Shares</u> *.* Unless otherwise specified in the applicable Placement Notice, settlement for sales
 of Placement Shares will occur on the first (1st) Trading Day (or such earlier day as is
 industry practice or as is required for regular-way trading) following the date on which
 such sales are made (each, a "  **<u>Settlement Date</u>** "). The amount of
 proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement
 Shares sold (the "  **<u>Net Proceeds</u>**") will be equal to the aggregate
 sales price received by the Agent, after deduction for (i) the Agent's commission,
 discount or other compensation for such sales payable by the Company pursuant to <u>Section 2</u> hereof, (ii) any other amounts due and payable by the Company to the Agent hereunder
 pursuant to <u>Section 8</u> hereof and (iii) any transaction fees imposed by any
 Governmental Authority (as defined below) in respect of such sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Delivery of Placement Shares</u>. On
 or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically
 transfer the Placement Shares being sold by crediting the account of the Agent's or
 its designee's account (provided the Agent shall have given the Company written notice
 of such designee on or prior to the Settlement Date) at The Depository Trust Company through
 its Deposit and Withdrawal at Custodian System or by such other means of delivery as may
 be mutually agreed upon by the parties hereto which in all cases shall be freely tradable,
 transferable, registered shares in good deliverable form. On each Settlement Date, the Agent
 will deliver the related Net Proceeds in same day funds to an account designated by the Company
 on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer
 agent (if applicable), defaults in its obligation to deliver Placement Shares on a Settlement
 Date, the Company agrees that, in addition to and in no way limiting the rights and obligations
 set forth in <u>Section 10(a)</u> hereto, it will (i) hold the Agent harmless
 against any loss, claim, damage, or expense (including reasonable and documented legal fees
 and expenses), as incurred, arising out of or in connection with such default by the Company
 or its transfer agent (as applicable), and (ii) pay to the Agent any commission, discount,
 or other compensation to which it would otherwise have been entitled absent such default.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Limitations on Offering Size</u> *.* Under no circumstances shall the Company cause or request the offer or sale of any Placement
 Shares if, after giving effect to the sale of such Placement Shares, the aggregate gross
 sales proceeds of Placement Shares sold pursuant to this Agreement would exceed the lesser
 of (A) the Maximum Amount and (B) the amount authorized from time to time to be
 issued and sold under this Agreement by the Company's board of directors, a duly authorized
 committee thereof or a duly authorized executive committee (such entity, the "  **<u>Company Authorization Body</u>** "). Under no circumstances shall the Company cause or request
 the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than
 the minimum price authorized from time to time by the Company Authorization Body.

6. <u>Representations and Warranties of the Company</u>. The Company represents
 and warrants to, and agrees with the Agent that as of the date of this Agreement and as of each Applicable
 Time (as defined below):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Registration Statement and Prospectus</u>.
 The Company and the transactions contemplated by this Agreement meet the requirements for
 and comply with the applicable conditions set forth in Form S-3 (including General Instructions
 I.A and I.B) under the Securities Act. The Registration Statement has been filed or will
 be filed with the Commission and has been declared or will be declared or deemed effective
 by the Commission under the Securities Act prior to the issuance of any Placement Notices
 by the Company. As of each Applicable Time, the Registration Statement is and will be effective.
 The Prospectus Supplement will name the Agent as the agent in the section entitled "Plan
 of Distribution." The Company has not received, and has no notice of, any order of
 the Commission preventing or suspending the use of the Registration Statement, or threatening
 or instituting proceedings for that purpose. The Registration Statement and the offer and
 sale of Placement Shares as contemplated hereby meet the requirements of Rule 415 under
 the Securities Act and comply in all material respects with said Rule. Any statutes, regulations,
 contracts or other documents that are required to be described in the Registration Statement
 or the Prospectus or to be filed as exhibits to the Registration Statement have been so described
 or filed. Copies of the Registration Statement, the Prospectus, and any such amendments or
 supplements and all documents incorporated by reference therein that were filed with the
 Commission on or prior to the date of this Agreement have been delivered, or are available
 through EDGAR, to the Agent and its counsel. The Company has not distributed and, prior to
 the later to occur of each Settlement Date and completion of the distribution of the Placement
 Shares, will not distribute any offering material in connection with the offering or sale
 of the Placement Shares other than the Registration Statement and the Prospectus and any
 Issuer Free Writing Prospectus (as defined below) to which the Agent has consented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>No Misstatement or Omission</u>. The
 Registration Statement, when it became or becomes effective, and the Prospectus, and any
 amendment or supplement thereto, on the date of such Prospectus or amendment or supplement,
 conformed and will conform in all material respects with the requirements of the Securities
 Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date,
 will conform in all material respects with the requirements of the Securities Act. The Registration
 Statement, when it became or becomes effective, did not, and will not, contain an untrue
 statement of a material fact or omit to state a material fact required to be stated therein
 or necessary to make the statements therein not misleading. The Prospectus and any amendment
 and supplement thereto related to the Placement Shares, on the date thereof and at each Applicable
 Time (defined below), did not or will not include an untrue statement of a material fact
 or omit to state a material fact necessary to make the statements therein, in light of the
 circumstances under which they were made, not misleading. The documents incorporated by reference
 in the Registration Statement, Prospectus or any Prospectus Supplement did not, and any further
 documents filed and incorporated by reference therein will not, when filed with the Commission,
 contain an untrue statement of a material fact or omit to state a material fact required
 to be stated in such document or necessary to make the statements in such document, in light
 of the circumstances under which they were made, not misleading. The foregoing shall not
 apply to statements in, or omissions from, any such document made in reliance upon, and in
 conformity with, information furnished to the Company by the Agent in writing specifically
 for use in the preparation thereof, it being understood and agreed that the only such information
 furnished by the Agent to the Company consists of the Agent Information (as defined below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Conformity with the Securities Act and Exchange Act</u>. The Registration Statement, the Prospectus, any Issuer Free Writing
 Prospectus or any amendment or supplement thereto, and any documents incorporated by reference
 in the Registration Statement, the Prospectus or any amendment or supplement thereto, when
 such documents were or are filed with the Commission under the Securities Act or the Exchange
 Act or became or become effective under the Securities Act, as the case may be, conformed
 or will conform in all material respects with the requirements of the Securities Act and
 the Exchange Act, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Exchange Matters</u>. The Company is
 subject to and in compliance in all material respects with the reporting requirements of
 Section 13 or Section 15(d) of the Exchange Act. The Common Stock is registered
 pursuant to Section 12(b) of the Exchange Act and is currently listed on the Exchange.
 The Company has taken no action designed to, or likely to have the effect of, terminating
 the registration of the Common Stock under the Exchange Act, delisting the Common Stock from
 the Exchange, nor has the Company received any notification that the Commission or the Exchange
 is contemplating terminating such registration or listing. To the Company's knowledge,
 it is in compliance with all applicable listing requirements of the Exchange. The Company
 has filed a Notification of Listing of Additional Shares with the Exchange with respect to
 the Placement Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Financial Information</u>. The consolidated
 financial statements of the Company included or incorporated by reference in the Registration
 Statement and the Prospectus together with the related notes and schedules, present fairly,
 in all material respects, the consolidated financial position of the Company as of the dates
 indicated and the consolidated results of operations, cash flows and changes in stockholders'
 equity of the Company for the periods specified and have been prepared in compliance with
 the requirements of the Securities Act and Exchange Act and in conformity with U.S. Generally
 Accepted Accounting Principles ("  **<u>GAAP</u>**") applied on a consistent
 basis during the periods involved, subject to, in the case of any unaudited financial statements,
 normal year-end adjustments and the absence of footnotes. The other financial and statistical
 data with respect to the Company and the Subsidiaries contained or incorporated by reference
 in the Registration Statement and the Prospectus are accurately and fairly presented in all
 material respects and prepared on a basis consistent in all material respects with the financial
 statements and books and records of the Company. There are no financial statements (historical
 or pro forma) that are required to be included or incorporated by reference in the Registration
 Statement, or the Prospectus that are not included or incorporated by reference therein as
 required. The Company and the Subsidiaries do not have any material liabilities or obligations,
 direct or contingent (including any off-balance sheet obligations), not described or incorporated
 by reference in the Registration Statement (excluding the exhibits thereto), and the Prospectus,
 which are required to be described therein. All disclosures contained or incorporated by
 reference in the Registration Statement and the Prospectus regarding "non-GAAP financial
 measures" (as such term is defined by the rules and regulations of the Commission)
 comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation
 S-K under the Securities Act, to the extent applicable. The interactive data in eXtensible
 Business Reporting Language included or incorporated by reference in the Registration Statement
 and the Prospectus fairly presents the information called for in all material respects and
 has been prepared in accordance with the Commission's rules and guidelines applicable
 thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Conformity with EDGAR Filing</u>. The
 Prospectus delivered to the Agent for use in connection with the sale of the Placement Shares
 pursuant to this Agreement will be identical to the versions of the Prospectus created to
 be transmitted to the Commission for filing via EDGAR, except to the extent permitted by
 Regulation S-T.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Organization and Good Standing.</u> The Company is duly organized, validly existing as a corporation and in good standing under
 the laws of its jurisdiction of incorporation. The Company is duly licensed or qualified
 as a foreign corporation for transaction of business and in good standing under the laws
 of each jurisdiction in which its ownership or lease of property or the conduct of its business
 requires such license or qualification, and has all corporate power and authority necessary
 to own or hold its properties and to conduct its business as described in the Registration
 Statement and the Prospectus, except where the failure to be so qualified or in good standing
 or have such power or authority would not, individually or in the aggregate, have a material
 adverse effect or would reasonably be expected to have a material adverse effect on or affecting
 the assets, business, operations, earnings, properties, condition (financial or otherwise),
 prospects, stockholders' equity or results of operations of the Company and the Subsidiaries
 (as defined below) taken as a whole, or prevent or materially interfere with consummation
 of the transactions contemplated hereby (a "  **<u>Material Adverse Effect</u>** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Subsidiaries</u>. Each of the Company's
 "subsidiaries" (for purposes of this Agreement, the Company's significant
 subsidiaries as such term is defined in rule 1-02 of Regulation S-X promulgated by the
 Commission) (each, a "  **<u>Subsidiary</u>**" and collectively, the "  **<u>Subsidiaries</u>** ")
 is duly organized, validly existing as a corporation or other business entity, as applicable,
 and in good standing (as applicable) under the laws of its jurisdiction of incorporation
 or organization, is duly licensed or qualified as a foreign corporation or other business
 entity for transaction of business and in good standing (as applicable) under the laws of
 each jurisdiction in which its respective ownership or lease of property or the conduct of
 its respective business requires such license or qualification, and has all corporate or
 similar power and authority necessary to own or hold its respective properties and to conduct
 its respective businesses as described in the Registration Statement and the Prospectus,
 except where the failure to be so qualified or in good standing (as applicable) or have such
 power or authority would not, individually or in the aggregate, have a Material Adverse Effect.
 Except as set forth in the Registration Statement and in the Prospectus, the Company owns,
 directly or indirectly, all of the equity interests of the Subsidiaries free and clear of
 any lien, charge, security interest, encumbrance, right of first refusal or other restriction,
 and all the equity interests of the Subsidiaries are, as applicable, validly issued and are
 fully paid, nonassessable and free of preemptive and similar rights. No Subsidiary is currently
 prohibited, directly or indirectly, from paying any dividends to the Company, from making
 any other distribution on such Subsidiary's capital stock, from repaying to the Company
 any loans or advances to such Subsidiary from the Company or from transferring any of such
 Subsidiary's property or assets to the Company or any other Subsidiary of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>No Violation or Default</u>. Neither
 the Company nor any of its Subsidiaries is (i) in violation of its charter or by-laws
 or similar organizational documents; (ii) in default, and no event has occurred that,
 with notice or lapse of time or both, would constitute such a default, in the due performance
 or observance of any term, covenant or condition contained in any indenture, mortgage, deed
 of trust, loan agreement or other agreement or instrument to which the Company or any of
 its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or
 to which any of the property or assets of the Company or any of its Subsidiaries is subject;
 or (iii) in violation of any law or statute or any judgment, order, rule or regulation
 of any Governmental Authority, except, in the case of each of clauses (ii) and (iii) above,
 for any such violation or default that would not, individually or in the aggregate, reasonably
 be expected to have a Material Adverse Effect. To the Company's knowledge, no other
 party under any material contract or other agreement to which it or any of its Subsidiaries
 is a party is in default in any respect thereunder where such default would have a Material
 Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>No Material Adverse Change</u>. Subsequent
 to the respective dates as of which information is given in the Registration Statement, the
 Prospectus and the Issuer Free Writing Prospectuses, if any (including any document deemed
 incorporated by reference therein), there has not been (i) any Material Adverse Effect
 or the occurrence of any development that the Company reasonably expects will result in a
 Material Adverse Effect, (ii) any transaction entered into by the Company or the Subsidiaries
 which is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation
 or liability, direct or contingent (including any off-balance sheet obligations), incurred
 by the Company or any Subsidiary, which is material to the Company and the Subsidiaries taken
 as a whole, (iv) any material change in the capital stock (other than (x) as a
 result of the sale of Placement Shares, (y) the issuance of equity awards under existing
 equity incentive plans and arrangements, and (z) the issuance of Common Stock upon the
 vesting, exercise or conversion of securities exercisable for, or convertible into, shares
 of Common Stock (including warrants and restricted stock units) outstanding as of the date
 hereof) or outstanding long-term indebtedness of the Company or any of its Subsidiaries or
 (v) any dividend or distribution of any kind declared, paid or made on the capital stock
 of the Company or any Subsidiary, other than in each case above in the ordinary course of
 business or as otherwise disclosed in the Registration Statement or Prospectus (including
 any document deemed incorporated by reference therein).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Capitalization</u> *.* The issued
 and outstanding shares of capital stock of the Company have been validly issued, are fully
 paid and nonassessable, other than as described in the Registration Statement or the Prospectus.
 None of the outstanding shares of capital stock of the Company were issued in violation of
 any preemptive rights, rights of first refusal or other similar rights to subscribe for or
 purchase securities of the Company. The Company has an authorized, issued and outstanding
 capitalization as set forth in the Registration Statement and the Prospectus as of the dates
 referred to therein (other than (x) as a result of the sale of Placement Shares, (y) the
 issuance of equity awards under existing equity incentive plans and arrangements, and (z) the
 issuance of Common Stock upon the vesting, exercise or conversion of securities exercisable
 for, or convertible into, shares of Common Stock (including warrants and restricted stock
 units) outstanding as of the date hereof) and such authorized capital stock conforms in all
 material respects to the description thereof set forth in the Registration Statement and
 the Prospectus. The description of the securities of the Company in the Registration Statement
 and the Prospectus is complete and accurate in all material respects. Except as disclosed
 in or contemplated by the Registration Statement or the Prospectus, as of the date referred
 to therein, the Company does not have outstanding any options to purchase, or any rights
 or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable
 for, or any contracts or commitments to issue or sell, any shares of capital stock or other
 securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>Due Authorization; Enforceability</u> *.* The Company has full legal right, power and authority to enter into this Agreement and perform
 the transactions contemplated hereby. This Agreement has been duly authorized, executed and
 delivered by the Company and is a legal, valid and binding agreement of the Company enforceable
 in accordance with its terms, except to the extent that enforceability may be limited by
 bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors'
 rights generally and by general equitable principles.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>Authorization of Placement Shares</u> *.* The Placement Shares, when issued and delivered pursuant to the terms approved by the
 board of directors of the Company or a duly authorized committee thereof, or a duly authorized
 executive committee, against payment therefor as provided herein, will be duly and validly
 authorized and issued and fully paid and nonassessable, free and clear of any pledge, lien,
 encumbrance, security interest or other claim (other than any pledge, lien, encumbrance,
 security interest or other claim from an act or omission of the Agent or a purchaser), including
 any statutory or contractual preemptive rights, resale rights, rights of first refusal or
 other similar rights, and will be registered pursuant to Section 12 of the Exchange
 Act, except for such rights as are disclosed in the Registration Statement or Prospectus.
 The Placement Shares, when issued, will conform in all material respects to the description
 thereof set forth in or incorporated into the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) <u>No Consents Required</u>. No consent,
 approval, authorization, order, registration or qualification of or with any Governmental
 Authority is required for the execution, delivery and performance by the Company of this
 Agreement, or the issuance and sale by the Company of the Placement Shares, except for such
 consents, approvals, authorizations, orders and registrations or qualifications (i) as
 have been obtained or made, (ii) as may be required under applicable state securities
 laws or by the by-laws and rules of the Financial Industry Regulatory Authority ("  **<u>FINRA</u>** ")
 or the Exchange in connection with the sale of the Placement Shares by the Agent, or (iii) as
 would not, individually or in the aggregate, reasonably be expected to materially adversely
 affect the consummation of the transaction contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) <u>No Preferential Rights</u>. Except
 as set forth in the Registration Statement and the Prospectus, (i) no person, as such
 term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act
 (each, a "  **<u>Person</u>** "), has the right, contractual or otherwise, to
 cause the Company to issue or sell to such Person any Common Stock or shares of any other
 capital stock or other securities of the Company (other than the issuance, grant or award
 of, and the issuance of shares of Common Stock upon the vesting, exercise or conversion of,
 restricted stock units, stock options, warrants or other securities described in the Registration
 Statement or Prospectus, including under the Company's stock option or benefit plans),
 (ii) no Person has any preemptive rights, resale rights, rights of first refusal, rights
 of co-sale, or any other rights (whether pursuant to a "poison pill" provision
 or otherwise) to purchase any Common Stock or shares of any other capital stock or other
 securities of the Company, (iii) other than this Agreement, no Person has the right
 to act as an underwriter or as a financial advisor to the Company in connection with the
 offer and sale of the Placement Shares hereunder, and (iv) no Person has the right,
 contractual or otherwise, to require the Company to register under the Securities Act any
 Common Stock or shares of any other capital stock or other securities of the Company, or
 to include any such shares or other securities in the Registration Statement or the offering
 contemplated thereby, whether as a result of the filing or effectiveness of the Registration
 Statement or the sale of the Placement Shares as contemplated thereby or otherwise, except
 for such rights as have been waived in writing on or prior to the date hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) <u>Independent Public Accounting Firm</u>.
 EisnerAmper LLP, (the "  **<u>Accountant</u>** "), whose report on the consolidated
 financial statements of the Company is filed with the Commission as part of the Company's
 most recent Annual Report on Form 10-K filed with the Commission and incorporated by
 reference into the Registration Statement and the Prospectus, are and, during the periods
 covered by their report, were an independent registered public accounting firm within the
 meaning of the Securities Act and the Public Company Accounting Oversight Board (United States).
 To the Company's knowledge, the Accountant is not in violation of the auditor independence
 requirements of the Sarbanes-Oxley Act of 2002 (the "  **<u>Sarbanes-Oxley Act</u>** ")
 with respect to the Company. The Accountant has not been engaged by the Company to perform
 any "prohibited activities" or provided to the Company any "non-audit services"
 (as defined in Section 10A of the Exchange Act).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) <u>Enforceability of Agreements</u>. All
 agreements between the Company and third parties expressly referenced in the Registration
 Statement and Prospectus are legal, valid and binding obligations of the Company or its applicable
 subsidiary enforceable in accordance with their respective terms, except to the extent that
 (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium
 or similar laws affecting creditors' rights generally and by general equitable principles
 and (ii) the indemnification provisions of certain agreements may be limited by federal
 or state securities laws or public policy considerations in respect thereof, except for any
 unenforceability that, individually or in the aggregate, would not have a Material Adverse
 Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) <u>No Litigation</u>. Except as set forth
 in the Registration Statement or the Prospectus, there are no actions, suits or proceedings
 by or before any Governmental Authority pending against the Company or its Subsidiaries,
 nor, to the Company's knowledge, any audits or investigations by or before any Governmental
 Authority to which the Company or a Subsidiary is a party or to which any property of the
 Company or any of its Subsidiaries is the subject that, individually or in the aggregate,
 if determined adversely to the Company or such Subsidiary, would reasonably be expected to
 have a Material Adverse Effect and, to the Company's knowledge, no such actions, suits,
 proceedings, audits or investigations are threatened or contemplated by any Governmental
 Authority or threatened by others that, individually or in the aggregate, if determined adversely
 to the Company or any of the Subsidiaries, would have a Material Adverse Effect; and (i) there
 are no current or pending audits, actions, suits or proceedings or, to the Company's
 knowledge, investigations by or before any Governmental Authority that are required under
 the Securities Act to be described in the Registration Statement and Prospectus that are
 not so described; and (ii) there are no contracts or other documents that are required
 under the Securities Act to be filed as exhibits to the Registration Statement that are not
 described in all material respects or filed as required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) <u>Consents and Permits</u>. Except as
 disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries
 have made all filings, applications and submissions required by, possesses and is operating
 in compliance with, all approvals, licenses, certificates, certifications, clearances, consents,
 grants, exemptions, marks, notifications, orders, permits and other authorizations issued
 by, the appropriate federal, state or foreign Governmental Authority (including, without
 limitation, the United States Food and Drug Administration (the "  **<u>FDA</u>** "),
 the European Medicines Agency ("  **<u>EMA</u>** "), the United States Drug Enforcement
 Administration or any other foreign, federal, state, provincial, court or local government
 or regulatory authorities including self-regulatory organizations engaged in the regulation
 of clinical trials, pharmaceuticals, biologics or biohazardous substances or materials) necessary
 for the ownership or lease of their respective properties or to conduct their respective
 businesses as described in the Registration Statement and the Prospectus (collectively, "  **<u>Permits</u>** "),
 except for such Permits the failure of which to possess, obtain, make or be in compliance
 with the same would not reasonably be expected to have a Material Adverse Effect; the Company
 and its Subsidiaries are in compliance with the terms and conditions of all such Permits,
 except where the failure to be in compliance would not reasonably be expected to have a Material
 Adverse Effect; all of the Permits are valid and in full force and effect, except where any
 invalidity, individually or in the aggregate, would not be reasonably expected to have a
 Material Adverse Effect; and neither the Company nor any of its Subsidiaries has received
 any written notice relating to the limitation, revocation, cancellation, suspension, modification
 or non-renewal of any such Permit which, singly or in the aggregate, if the subject of an
 unfavorable decision, ruling or finding, would reasonably be expected to have a Material
 Adverse Effect. To the extent required by applicable laws and regulations of the FDA, the
 Company or the applicable Subsidiary has submitted to the FDA an Investigational New Drug
 Application or amendment or supplement thereto for each clinical trial it has conducted or
 sponsored or is conducting or sponsoring; all such submissions were in material compliance
 with applicable laws and rules and regulations when submitted and no material deficiencies
 that remain outstanding have been asserted by the FDA with respect to any such submissions.
 Neither the Company, any of its Subsidiaries nor, to the Company's knowledge, any of
 their respective directors, officers, employees or agents acting on behalf of the Company
 has been the subject of an FDA debarment proceeding. To the Company's knowledge, neither
 the Company nor any of its Subsidiaries has been nor is now subject to the FDA's Application
 Integrity Policy. To the Company's knowledge, neither the Company, any of its Subsidiaries
 nor any of its directors, officers, employees or agents acting on behalf of the Company has
 made, or caused the making of, any false statements on, or material omissions from, any other
 records or documentation prepared or maintained to comply with the requirements of the FDA,
 EMA or any other Governmental Authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) <u>Regulatory Filings</u>. Except as disclosed
 in the Registration Statement and the Prospectus, neither the Company nor any of its Subsidiaries
 has failed to file with the applicable Governmental Authorities (including, without limitation,
 the FDA, EMA, or any foreign, federal, state, provincial or local Governmental Authority
 performing functions similar to those performed by the FDA) any required filing, declaration,
 listing, registration, report or submission, except for such failures that, individually
 or in the aggregate, would not reasonably be expected to have a Material Adverse Effect;
 and except as disclosed in the Registration Statement and the Prospectus, all such filings,
 declarations, listings, registrations, reports or submissions were in compliance with applicable
 laws when filed and no deficiencies have been asserted by any applicable regulatory authority
 with respect to any such filings, declarations, listings, registrations, reports or submissions,
 except for any deficiencies that, individually or in the aggregate, would not reasonably
 be expected to have a Material Adverse Effect. The Company has operated and currently is,
 in all material respects, in compliance with the United States Federal Food, Drug, and Cosmetic
 Act, all applicable rules and regulations of the FDA, EMA and other federal, state,
 local and foreign Governmental Authority exercising comparable authority. The Company has
 no knowledge of any studies, tests or trials not described in the Registration Statement
 and the Prospectus the results of which reasonably call into question in any material respect
 the results of the studies, tests and trials described in the Registration Statement and
 the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) <u>Intellectual Property</u>. Except as
 disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries
 own, possess, license or have other rights to use all foreign and domestic patents, patent
 applications, trade and service marks, trade and service mark registrations, trade names,
 copyrights, licenses, inventions, trade secrets, technology, Internet domain names,
 know-how and other intellectual property (collectively, the "  **<u>Intellectual Property</u>** "),
 necessary for the conduct of their respective businesses as now conducted except to the extent
 that the failure to own, possess, license or otherwise hold rights to use such Intellectual
 Property would not, individually or in the aggregate, have a Material Adverse Effect. Except
 as disclosed in the Registration Statement and the Prospectus (i) to the Company's
 knowledge, there is no infringement by third parties of any such Intellectual Property that
 is owned by the Company or its Subsidiaries; (ii) there is no pending or, to the Company's
 knowledge, threatened action, suit, proceeding or claim by others challenging the Company's
 and its Subsidiaries' rights in or to any such Intellectual Property that is owned
 by the Company or any of its Subsidiaries; (iii) there is no pending or, to the Company's
 knowledge, threatened action, suit, proceeding or claim by others challenging the validity
 or scope of any such Intellectual Property that is owned by the Company or any of its Subsidiaries;
 (iv) there is no pending or, to the Company's knowledge, threatened action, suit,
 proceeding or claim by others that the Company and its Subsidiaries infringe or otherwise
 violate any patent, trademark, copyright, trade secret or other proprietary rights of others;
 (v) to the Company's knowledge, there is no third-party U.S. patent or published
 U.S. patent application which contains claims for which an Interference Proceeding (as defined
 in 35 U.S.C. § 135) has been commenced against any patent or patent application described
 in the Prospectus as being owned by the Company; and (vi) the Company and its Subsidiaries
 have complied with the terms of each agreement pursuant to which Intellectual Property has
 been licensed to the Company or such Subsidiary, and all such agreements are in full force
 and effect, except, in the case of any of clauses (i)-(vi) above, as would not, individually
 or in the aggregate, result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Clinical Studies</u>. Except as disclosed
 in the Registration Statement and the Prospectus, the preclinical studies and tests and clinical
 trials conducted by or, to the Company' knowledge, on behalf of or sponsored by the
 Company or its Subsidiaries, or, to the Company' knowledge, in which the Company or
 its Subsidiaries have participated, that are described in the Registration Statement and
 Prospectus, or the results of which are referred to the Registration Statement and Prospectus,
 if applicable, were, and, if still pending, are being conducted in all material respects
 in accordance with the experimental protocols, procedures and controls pursuant to, where
 applicable, accepted professional and scientific standards for products or product candidates
 comparable to those being developed by the Company and all applicable statutes, rules and
 regulations of the U.S. Food and Drug Administration and comparable regulatory agencies outside
 of the United States to which they are subject, including the European Medicines Agency (collectively,
 the "  **<u>Regulatory Authorities</u>**") and all applicable statutes, rules and
 regulations of the Regulatory Authorities and Good Clinical Practice and Good Laboratory
 Practice requirements; the descriptions of such studies, tests and trials, and the results
 thereof, contained in the Registration Statement and the Prospectus are accurate and complete
 in all material respects and fairly present in all material respects the data derived thereof;
 the Company is not aware of any tests, studies or trials not described in the Registration
 Statement and the Prospectus, the results of which are inconsistent with or reasonably call
 into question the results of the tests, studies and trials described in the Registration
 Statement and the Prospectus; and the Company and its Subsidiaries have not received any
 written notice or correspondence from the FDA or any foreign, state or local Governmental
 Authority exercising comparable authority or any institutional review board or comparable
 authority requiring or threatening the termination, suspension, clinical hold or material
 modification of any tests, studies or trials, except in each case as would not, individually
 or in the aggregate, reasonably be expected to result in a Material Adverse Effect. To the
 Company's knowledge, the manufacturing facilities and operations of its suppliers are
 operated in compliance in all material respects with all applicable statutes, rules, regulations
 and policies of the FDA or any foreign, state or local Governmental Authority exercising
 comparable authority outside of the United States to which the Company is subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) <u>Market Capitalization</u>. At the time
 the Registration Statement was originally declared effective, and at the time the Company's
 most recent Annual Report on Form 10-K was filed with the Commission, the Company met
 the then applicable requirements for the use of Form S-3 under the Securities Act, including,
 but not limited to, General Instruction I.B.1 of Form S-3. The Company is not a shell
 company (as defined in Rule 405 under the Securities Act) and has not been a shell company
 for at least 12 calendar months previously and if it has been a shell company at any time
 previously, has filed current Form 10 information (as defined in Instruction I.B.6 of
 Form S-3) with the Commission at least 12 calendar months previously reflecting its
 status as an entity that is not a shell company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) <u>FINRA Matters</u>. Neither the Company
 nor any of the Subsidiaries is required to register as a "broker" or "dealer"
 in accordance with the provisions of the Exchange Act and do not, directly or indirectly
 through one or more intermediaries, control or have any other association with (within the
 meaning of Article I of the By-laws of FINRA) any member firm of FINRA. No relationship,
 direct or indirect, exists between or among the Company, on the one hand, and the directors,
 officers or shareholders of the Company, on the other hand, which is required by the rules of
 FINRA to be described in the Registration Statement and the Prospectus, which is not so described.
 The information provided to the Agent by the Company, its counsel, and its officers and directors
 for purposes of the Agent's compliance with applicable FINRA rules in connection
 with the offering of the Placement Shares is true, complete, and correct and compliant with
 FINRA's rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) <u>No Material Defaults</u>. Neither the
 Company nor any of the Subsidiaries has defaulted on any installment on indebtedness for
 borrowed money or on any rental on one or more long-term leases, which defaults, individually
 or in the aggregate, would reasonably be expected to have a Material Adverse Effect. The
 Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange
 Act since the filing of its last Annual Report on Form 10-K, indicating that it (i) has
 failed to pay any dividend or sinking fund installment on preferred stock or (ii) has
 defaulted on any installment on indebtedness for borrowed money or on any rental on one or
 more long-term leases, which defaults, individually or in the aggregate, would reasonably
 be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) <u>Certain Market Activities</u>. Neither
 the Company, nor any of the Subsidiaries, nor to the Company's knowledge any of their
 respective directors, officers or controlling persons has taken, directly or indirectly any
 action designed, or that has constituted or would reasonably be expected to cause or result
 in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of
 (A) Zcash ("  **<u>ZEC</u>**") or (B) any security of the Company
 to facilitate the sale or resale of the Placement Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa) <u>No Reliance</u>. The Company has not
 relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice
 in connection with the offering and sale of Placement Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb) <u>Taxes</u>. The Company and each of
 its Subsidiaries have filed all federal, state, local and foreign tax returns which have
 been required to be filed and paid all taxes shown thereon through the date hereof, to the
 extent that such taxes have become due and are not being contested in good faith, except
 where the failure to so file or pay would not have a Material Adverse Effect. Except as otherwise
 disclosed in or contemplated by the Registration Statement or the Prospectus, no tax deficiency
 has been determined adversely to the Company or any of its Subsidiaries which has had, or
 would reasonably be expected to have, individually or in the aggregate, a Material Adverse
 Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency,
 penalty or assessment which has been or might be asserted or threatened against it which
 would have a Material Adverse Effect. The charges, accruals and reserves on the books of
 the Company and its Subsidiaries in respect of any income or other tax liability for any
 years not finally determined are adequate to meet any assessments or re-assessments for additional
 tax for any years not finally determined, except to the extent of any inadequacy that would
 not reasonably be expected to result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cc) <u>Title to Real and Personal Property</u>.
 Except as set forth in the Registration Statement or the Prospectus, the Company and its
 Subsidiaries have good and marketable title in fee simple or other comparable valid title
 to all items of real property owned by them, good and valid title to all personal property
 described in the Registration Statement or Prospectus as being owned by them that are material
 to the ordinary course of business of the Company and the Subsidiaries, in each case free
 and clear of all liens, encumbrances and claims, except those matters that (i) do not
 materially interfere with the use made and proposed to be made of such property by the Company
 and any of its Subsidiaries or (ii) would not, individually or in the aggregate, reasonably
 be expected to have a Material Adverse Effect. Any real or personal property described in
 the Registration Statement or Prospectus as being leased by the Company and any of its Subsidiaries
 is held by them under valid, existing and enforceable leases, except those that (A) do
 not materially interfere with the use made or proposed to be made of such property by the
 Company or any of its Subsidiaries or (B) would not be reasonably expected, individually
 or in the aggregate, to have a Material Adverse Effect. To the best of the Company's
 knowledge, each of the properties of the Company and its Subsidiaries complies with all applicable
 codes, laws and regulations (including, without limitation, building and zoning codes, laws
 and regulations and laws relating to access to such properties), except if and to the extent
 disclosed in the Registration Statement or Prospectus or except for such failures to comply
 that would not, individually or in the aggregate, reasonably be expected to interfere in
 any material respect with the use made and proposed to be made of such property by the Company
 and its Subsidiaries or otherwise have a Material Adverse Effect. None of the Company or
 its Subsidiaries has received from any Governmental Authorities any notice of any condemnation
 of, or zoning change affecting, the properties of the Company and its Subsidiaries, and to
 the Company's knowledge, there is no such condemnation or zoning change which is threatened,
 except for such that would not reasonably be expected to interfere in any material respect
 with the use made and proposed to be made of such property by the Company and its Subsidiaries
 or otherwise have a Material Adverse Effect, individually or in the aggregate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd) <u>Environmental Laws</u>. Except as
 set forth in the Registration Statement or the Prospectus, the Company and its Subsidiaries
 (i) are in compliance with any and all applicable federal, state, local and foreign
 laws, rules, regulations, decisions and orders relating to the protection of human health
 and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
 (collectively, "  **<u>Environmental Laws</u>** "); (ii) have received and
 are in compliance with all permits, licenses or other approvals required of them under applicable
 Environmental Laws to conduct their respective businesses as described in the Registration
 Statement and the Prospectus; and (iii) have not received notice of any actual or potential
 liability for the investigation or remediation of any disposal or release of hazardous or
 toxic substances or wastes, pollutants or contaminants, except, in the case of any of clauses
 (i), (ii) or (iii) above, for any such failure to comply or failure to receive
 required permits, licenses, other approvals or liability as would not, individually or in
 the aggregate, reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee) <u>Disclosure Controls</u>. The Company
 and each of its Subsidiaries maintain systems of internal accounting controls sufficient
 to provide reasonable assurance that (i) transactions are executed in accordance with
 management's general or specific authorizations; (ii) transactions are recorded
 as necessary to permit preparation of financial statements in conformity with GAAP and to
 maintain asset accountability; (iii) access to assets is permitted only in accordance
 with management's general or specific authorization; and (iv) the recorded accountability
 for assets is compared with the existing assets at reasonable intervals and appropriate action
 is taken with respect to any differences. As of the end of the Company's most recently
 completed fiscal year, the Company's internal control over financial reporting was
 effective and as of the end of the Company's most recently completed fiscal year the
 Company is not aware of any material weaknesses in its internal control over financial reporting
 (other than as set forth in the Prospectus). Since the date of the latest audited financial
 statements of the Company included in the Prospectus, there has been no change in the Company's
 internal control over financial reporting that has materially adversely affected, or is reasonably
 likely to materially adversely affect, the Company's internal control over financial
 reporting (other than as set forth in the Prospectus). The Company has established disclosure
 controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the
 Company and designed such disclosure controls and procedures to ensure that material information
 relating to the Company and each of its Subsidiaries is made known to the certifying officers
 by others within those entities, particularly during the period in which the Company's
 Annual Report on Form 10 K or Quarterly Report on Form 10-Q, as the case may be,
 is being prepared. The Company's certifying officers have evaluated the effectiveness
 of the Company's disclosure controls and procedures as of a date within 90 days prior
 to the filing date of the Annual Report on Form 10 K for the fiscal year most recently
 ended (such date, the "  **<u>Evaluation Date</u>** "). The Company presented
 in its Annual Report on Form 10 K for the fiscal year most recently ended the conclusions
 of the certifying officers about the effectiveness of the disclosure controls and procedures
 based on their evaluations as of the Evaluation Date and the disclosure controls and procedures
 are effective. Since the Evaluation Date, there have been no significant changes in the Company's
 internal controls (as such term is defined in Item 307(b) of Regulation S K under the
 Securities Act) or, to the Company's knowledge, in other factors that could significantly
 affect the Company's internal controls.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ff) <u>Sarbanes-Oxley</u>. There is and has
 been no failure on the part of the Company or any of the Company's directors or officers,
 in their capacities as such, to comply in all material respects with any applicable provisions
 of the Sarbanes-Oxley Act and the rules and regulations promulgated thereunder. Each
 of the principal executive officer and the principal financial officer of the Company (or
 each former principal executive officer of the Company and each former principal financial
 officer of the Company as applicable) has made all certifications required by Sections 302
 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements
 and other documents required to be filed by it or furnished by it to the Commission. For
 purposes of the preceding sentence, "principal executive officer" and "principal
 financial officer" shall have the meanings given to such terms in the Sarbanes-Oxley
 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(gg) <u>Finder's Fees</u>. Neither the
 Company nor any of the Subsidiaries has incurred any liability for any finder's fees,
 brokerage commissions or similar payments in connection with the transactions herein contemplated,
 except as may otherwise exist with respect to the Agent pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(hh) <u>Labor Disputes</u>. No labor disturbance
 by or dispute with employees of the Company or any of its Subsidiaries exists or, to the
 knowledge of the Company, is threatened which would reasonably be expected to result in a
 Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Investment Company Act</u>. Neither
 the Company nor any of the Subsidiaries is or, after giving effect to the offering and sale
 of the Placement Shares and the application of the proceeds thereof, will be an "investment
 company" or an entity "controlled" by an "investment company,"
 as such terms are defined in the Investment Company Act of 1940, as amended (the "  **<u>Investment Company Act</u>** "). The Company shall conduct its business in a manner so that it
 will not become required to register as an "investment company" as such term
 is defined in the Investment Company Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(jj) <u>Operations</u>. The operations of
 the Company and its Subsidiaries are and have been conducted at all times in compliance in
 all material respects with applicable financial record keeping and reporting requirements
 of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering
 statutes of all applicable jurisdictions to which the Company or its Subsidiaries are subject,
 the applicable rules and regulations thereunder and any applicable related or similar
 rules, regulations or guidelines, issued, administered or enforced by any Governmental Authority
 (collectively, the "  **<u>Money Laundering Laws</u>** "); and no action, suit
 or proceeding by or before any Governmental Authority involving the Company or any of its
 Subsidiaries with respect to a violation of the Money Laundering Laws by the Company or its
 Subsidiaries is pending or, to the knowledge of the Company, threatened.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(kk) <u>Off-Balance Sheet Arrangements</u>.
 There are no transactions, arrangements and other relationships between and/or among the
 Company, and/or, to the knowledge of the Company, any of its affiliates and any unconsolidated
 entity, including, but not limited to, any structured finance, special purpose or limited
 purpose entity (each, an "  **<u>Off-Balance Sheet Transaction</u>**") that
 could reasonably be expected to affect materially the Company's liquidity or the availability
 of or requirements for its capital resources, including those Off-Balance Sheet Transactions
 described in the Commission's Statement about Management's Discussion and Analysis
 of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61),
 required to be described in the Registration Statement and the Prospectus which have not
 been described as required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ll) <u>Other Underwriter Agreements</u>.
 The Company is not a party to any agreement with an agent or underwriter for any other "at
 the market", equity line of credit or other continuous equity transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(mm) <u>ERISA</u>. To the knowledge of the
 Company, each material employee benefit plan, within the meaning of Section 3(3) of
 the Employee Retirement Income Security Act of 1974, as amended ("  **<u>ERISA</u>** "),
 that is maintained, administered or contributed to by the Company or any of its Subsidiaries
 for employees or former employees of the Company and any of its Subsidiaries has been maintained
 in material compliance with its terms and the requirements of any applicable statutes, orders,
 rules and regulations, including but not limited to ERISA and the Internal Revenue Code
 of 1986, as amended (the "  **<u>Code</u>** "); no prohibited transaction, within
 the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which
 would result in a material liability to the Company with respect to any such plan excluding
 transactions effected pursuant to a statutory or administrative exemption; and for each such
 plan that is subject to the funding rules of Section 412 of the Code or Section 302
 of ERISA, no "accumulated funding deficiency" as defined in Section 412
 of the Code has been incurred, whether or not waived, and the fair market value of the assets
 of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds
 the present value of all benefits accrued under such plan determined using reasonable actuarial
 assumptions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(nn) <u>Forward-Looking Statements</u>. Each
 financial or operational projection or other forward-looking statement (within the meaning
 of Section 27A of the Securities Act and Section 21E of the Exchange Act) (a "  **<u>Forward-Looking Statement</u>**") contained in the Registration Statement and the Prospectus (i) was
 so included by the Company in good faith and with a reasonable basis after due consideration
 by the Company of the underlying assumptions, estimates and other applicable facts and circumstances
 and (ii) to the extent required under the Exchange Act, is accompanied by meaningful
 cautionary statements identifying those factors that could cause actual results to differ
 materially from those in such Forward-Looking Statement. No Forward-Looking Statement was
 made with the knowledge of a director or executive officer of the Company that such Forward-Looking
 Statement was false or misleading when made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(oo) <u>Agent Purchases</u>. The Company acknowledges
 and agrees that the Agent has informed the Company that the Agent may, to the extent permitted
 under the Securities Act and the Exchange Act, purchase and sell Common Stock for its own
 account while this Agreement is in effect, provided, that the Company shall not be deemed
 to have authorized or consented to any such purchases or sales by the Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(pp) <u>Margin Rules</u>. Neither the issuance,
 sale and delivery of the Placement Shares nor the application of the proceeds thereof by
 the Company as described in the Registration Statement and the Prospectus will violate Regulation
 T, U or X of the Board of Governors of the Federal Reserve System or any other regulation
 of such Board of Governors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(qq) <u>Insurance</u>. Except as would not
 reasonably be expected to have a Material Adverse Effect, the Company and each of its Subsidiaries
 carry, or are covered by, insurance in such amounts and covering such risks as the Company
 and each of its Subsidiaries reasonably believe are adequate for the conduct of their properties
 and are customary for companies engaged in similar businesses in similar industries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(rr) <u>No Improper Practices</u>. (i) Neither
 the Company nor the Subsidiaries, nor any director or officer of the Company or any Subsidiary
 nor, to the Company's knowledge, any employee, agent, affiliate or other person acting
 on behalf of the Company or any Subsidiary has, in the past five years, made any unlawful
 contributions to any candidate for any political office (or failed fully to disclose any
 contribution in violation of applicable law) or made any contribution or other payment to
 any official of, or candidate for, any federal, state, municipal, or foreign office or other
 person charged with similar public or quasi-public duty in violation of any applicable law
 or of the character required to be disclosed in the Registration Statement and the Prospectus;
 (ii) no relationship, direct or indirect, exists between or among the Company or any
 Subsidiary or, to the Company's knowledge, any affiliate of any of them, on the one
 hand, and the directors, officers and stockholders of the Company or any Subsidiary, on the
 other hand, that is required by the Securities Act to be described in the Registration Statement
 and the Prospectus that is not so described; (iii) except as described in the Registration
 Statement and the Prospectus, there are no material outstanding loans or advances or material
 guarantees of indebtedness by the Company or any Subsidiary to or for the benefit of any
 of their respective officers or directors or any of the members of the families of any of
 them; and (iv) the Company has not offered, or caused any placement agent to offer,
 Common Stock to any person with the intent to influence unlawfully (A) a customer or
 supplier of the Company or any Subsidiary to alter the customer's or supplier's
 level or type of business with the Company or any Subsidiary or (B) a trade journalist
 or publication to write or publish favorable information about the Company or any Subsidiary
 or any of their respective products or services, and (v) neither the Company nor any
 Subsidiary nor any director, officer or employee of the Company or any Subsidiary nor, to
 the Company's knowledge, any agent, affiliate or other person acting on behalf of the
 Company or any Subsidiary has (A) violated or is in violation of any applicable provision
 of the U.S. Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010, as
 amended, or any other applicable anti-bribery or anti-corruption law (collectively, "  **<u>Anti-Corruption Laws</u>** "), (B) promised, offered, provided, attempted to provide or authorized
 the provision of anything of value, directly or indirectly, to any person for the purpose
 of obtaining or retaining business, influencing any act or decision of the recipient, or
 securing any improper advantage; or (C) made any payment of funds of the Company or
 any Subsidiary or received or retained any funds in violation of any Anti-Corruption Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ss) <u>Status Under the Securities Act</u>.
 The Company was not and is not an ineligible issuer as defined in Rule 405 under the
 Securities Act at the times specified in Rules 164 and 433 under the Securities Act
 in connection with the offering of the Placement Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(tt) <u>No Misstatement or Omission in an Issuer Free Writing Prospectus</u>. Each Issuer Free Writing Prospectus, as of its issue
 date and as of each Applicable Time (as defined below), did not, does not and will not include
 any information that conflicted, conflicts or will conflict with the information contained
 in the Registration Statement or the Prospectus, including any incorporated document deemed
 to be a part thereof that has not been superseded or modified. The foregoing sentence does
 not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon
 and in conformity with written information furnished to the Company by the Agent specifically
 for use therein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(uu) <u>No Conflicts</u>. Neither the execution
 of this Agreement, nor the issuance, offering or sale of the Placement Shares in accordance
 with this Agreement, nor the consummation of any of the transactions contemplated herein
 and therein, nor the compliance by the Company with the terms and provisions hereof and thereof
 will conflict with, or will result in a breach of, any of the terms and provisions of, or
 has constituted or will constitute a default under, or has resulted in or will result in
 the creation or imposition of any lien, charge or encumbrance upon any property or assets
 of the Company pursuant to the terms of any contract or other agreement to which the Company
 may be bound or to which any of the property or assets of the Company is subject, except
 (i) such conflicts, breaches or defaults as may have been waived or consented to and
 (ii) such conflicts, breaches and defaults, and liens, charges or encumbrances, that
 would not reasonably be expected to have a Material Adverse Effect; nor will such action
 result (x) in any violation of the provisions of the organizational or governing documents
 of the Company, or (y) in any violation of the provisions of any statute or any order,
 rule or regulation applicable to the Company or of any Governmental Authority having
 jurisdiction over the Company other than, with respect to this clause (y) only, any
 violation that would not have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vv) <u>Sanctions</u>. (i) The Company
 represents that, neither the Company nor any of its Subsidiaries (collectively, the "  **<u>Entity</u>** ")
 or any director or officer of the Company, nor, to the Company's knowledge, any employee,
 agent, affiliate or representative of the Company, is a government, individual, or entity
 (in this paragraph (vv), "  **<u>Person</u>**") that is, or is owned or controlled
 by a Person that is:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) the subject of any sanctions administered
 or enforced by the U.S. Department of Treasury's Office of Foreign Assets Control ("  **<u>OFAC</u>** "),
 the United Nations Security Council, the European Union, His Majesty's Treasury, or
 other relevant sanctions authorities, including, without limitation, designation on OFAC's
 Specially Designated Nationals and Blocked Persons List or OFAC's Foreign Sanctions
 Evaders List (as amended, collectively, "  **<u>Sanctions</u>** "), nor

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) located, organized or resident in a country
 or territory that is the subject of Sanctions that broadly prohibit dealings with that country
 or territory (including, without limitation, Cuba, Iran, North Korea, Syria, the so-called
 Donetsk People's Republic, the so-called Luhansk People's Republic, the Crimea
 Region of Ukraine, the non-government controlled areas of the Zaporizhzhia and Kherson Regions
 of Ukraine (or any other Covered Region of Ukraine identified pursuant to Executive Order
 14065)) (the "  **<u>Sanctioned Countries</u>** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Entity represents and covenants that
 it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute
 or otherwise make available such proceeds to any subsidiary, joint venture partner or other
 Person:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) to fund or facilitate any activities or
 business of or with any Person or in any country or territory that, at the time of such funding
 or facilitation, is the subject of Sanctions or is a Sanctioned Country; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) in any other manner that will result in
 a violation of Sanctions by any Person (including any Person participating in the offering,
 whether as underwriter, advisor, investor or otherwise).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Except as disclosed in the Registration
 Statement and the Prospectus, for the past five years, it has not engaged in, is not now
 knowingly engaging in, and will not knowingly engage in, any dealings or transactions with
 any Person, or in any country or territory, that at the time of the dealing or transaction
 is or was the subject of Sanctions or is or was a Sanctioned Country.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ww) <u>Export Compliance</u>. The Company
 and each of its Subsidiaries has not, nor has any director or officer of the Company, nor,
 to the Company's knowledge, any agent, employee or other Person acting on behalf of
 the Company or any of its Subsidiaries violated or failed to comply with any applicable law
 related to the export or reexport of goods (including hardware, software, technology and
 data), services and know-how, except in such cases as would not reasonably be expected, individually
 or in the aggregate, to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xx) <u>Stock Transfer Taxes</u>. On each
 Settlement Date, all stock transfer or other taxes (other than income taxes) which are required
 to be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder
 will be, or will have been, fully paid or provided for by the Company and all laws imposing
 such taxes will be or will have been complied with in all material respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(yy) <u>Compliance with Laws</u>. Each of
 the Company and its Subsidiaries: (A) is and at all times has been in compliance with
 all statutes, rules, or regulations applicable to the ownership, testing, development, manufacture,
 packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for
 sale, storage, import, export or disposal of any product manufactured or distributed by the
 Company or its Subsidiaries ("  **<u>Applicable Laws</u>** "), except as could
 not, individually or in the aggregate, reasonably be expected to result in a Material Adverse
 Effect; (B) has not received any FDA Form 483, notice of adverse finding, warning
 letter, untitled letter or other correspondence or notice from the FDA or any other Governmental
 Authority alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates,
 approvals, clearances, authorizations, permits and supplements or amendments thereto required
 by any such Applicable Laws ("  **<u>Authorizations</u>** "); (C) possesses
 all material Authorizations and such Authorizations are valid and in full force and effect
 and are not in material violation of any term of any such Authorizations; (D) has not
 received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
 arbitration or other action from any Governmental Authority or third party alleging that
 any product operation or activity is in violation of any Applicable Laws or Authorizations
 and has no knowledge that any such Governmental Authority or third party is considering any
 such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has
 not received notice that any Governmental Authority has taken, is taking or intends to take
 action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any
 such Governmental Authority is considering such action; (F) has filed, obtained, maintained
 or submitted all material reports, documents, forms, notices, applications, records, claims,
 submissions and supplements or amendments as required by any Applicable Laws or Authorizations
 and that all such reports, documents, forms, notices, applications, records, claims, submissions
 and supplements or amendments were complete and correct on the date filed (or were corrected
 or supplemented by a subsequent submission); and (G) has not, either voluntarily or
 involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued,
 any recall, market withdrawal or replacement, safety alert, post sale warning, "dear
 healthcare provider" letter, or other notice or action relating to the alleged lack
 of safety or efficacy of any product or any alleged product defect or violation and, to the
 Company's knowledge, no third party has initiated, conducted or intends to initiate
 any such notice or action, except in each case as would not reasonably be expected to have
 a Material Adverse Effect on the business of the Company or the business or legal environment
 under which the Company operates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(zz) <u>Statistical and Market-Related Data</u>. 
 The statistical, demographic and market-related data included in the Registration Statement
 and Prospectus are based on or derived from sources that the Company believes to be reliable
 and accurate or represent the Company's good faith estimates that are made on the basis
 of data derived from such sources.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aaa) <u>Cybersecurity</u>. Except as disclosed
 in the Registration Statement or Prospectus, and except as would not, individually or in
 the aggregate, have a Material Adverse Effect, (i) the Company and its Subsidiaries'
 information technology assets and equipment, computers, systems, networks, hardware, software,
 websites, applications, and databases (collectively, "  **<u>IT Systems</u>** ")
 are adequate for, and operate and perform in all material respects as required in connection
 with the operation of the business of the Company and each of its Subsidiaries as currently
 conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs,
 malware and other corruptants, (ii) the Company and its Subsidiaries have implemented
 and maintained commercially reasonable physical, technical and administrative controls, policies,
 procedures, and safeguards to maintain and protect their material confidential information
 and the integrity, continuous operation, redundancy and security of all IT Systems and data,
 including all "Personal Data" (defined below) and all sensitive, confidential
 or regulated data ("  **<u>Confidential Data</u>**") used in connection with
 their businesses, and (iii) there have been no breaches, violations, outages or unauthorized
 uses of or accesses to the same, except for those that have been remedied without material
 cost or liability or the duty to notify any other person, nor any incidents under internal
 review relating to the same. "  **<u>Personal Data</u>**" means (i) a natural
 person's name, street address, telephone number, e-mail address, photograph, social
 security number or tax identification number, driver's license number, passport number,
 credit card number, bank information, or customer or account number; (ii) any information
 which would qualify as "personally identifying information" under the Federal
 Trade Commission Act, as amended; (iii) "personal data" as defined by the
 General Data Protection Regulation ("  **<u>GDPR</u>** "); (iv) any information
 which would qualify as "protected health information" under the Health Insurance
 Portability and Accountability Act of 1996, as amended by the Health Information Technology
 for Economic and Clinical Health Act (collectively, "  **<u>HIPAA</u>** "); (v) any
 "personal information" as defined by the California Consumer Privacy Act ("  **<u>CCPA</u>** ");
 and (vi) any other piece of information that allows the identification of such natural
 person, or his or her family, or permits the collection or analysis of any data related to
 an identified person's health or sexual orientation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bbb) <u>Compliance with Data Privacy Laws</u>.
 Except as disclosed in the Registration Statement or Prospectus, and except as would not,
 individually or in the aggregate, have a Material Adverse Effect, (i) the Company and
 its Subsidiaries are in material compliance with all applicable state and federal data privacy
 and security laws and regulations, including without limitation HIPAA, CCPA, and the European
 Union GDPR (EU 2016/679) (collectively, the "  **<u>Privacy Laws</u>** "), (ii) the
 Company has in place, complies with, and takes appropriate steps to ensure compliance in
 all material respects with their policies and procedures relating to data privacy and security
 and the collection, storage, use, processing, disclosure, handling, and analysis of Personal
 Data and Confidential Data (the "  **<u>Policies</u>** "), (iii) the Company
 has made all disclosures to users or customers required by Privacy laws, and none of such
 disclosures made or contained in any Policy have been inaccurate or in violation of any Privacy
 Laws in any material respect, and (iv) neither the Company nor any subsidiary has received
 written notice of any actual or potential liability under or relating to, or actual or potential
 violation of, any of the Privacy Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ccc) <u>Crypto Assets and Related Third-Party Arrangements</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Company owns, directly or indirectly,
 and has good and valid title to all material Crypto Assets (as defined below) reflected in
 its financial statements or otherwise held by the Company as disclosed in the Registration
 Statement or the Prospectus, free and clear of all liens, encumbrances, pledges, and security
 interests, other than arising under applicable laws or as disclosed in the Registration Statement
 or the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Company holds Crypto Assets either
 (i) in digital wallets or cold storage under its sole control, or (ii) through
 custodial arrangements with Gemini Trust Company, LLC (the "  **<u>Custodian</u>** "),
 which is subject to a written agreement with the Company that includes provisions addressing
 fiduciary duties (as applicable), asset segregation, loss and theft protections, incident
 reporting, and compliance with applicable law. To the Company's knowledge, the Custodian
 is duly authorized or registered to the extent required under applicable U.S. federal or
 state law to perform Crypto Asset custody services and complies in all material respects
 with applicable regulatory requirements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Company has implemented internal controls,
 security protocols, and oversight procedures designed to safeguard its Crypto Assets, manage
 operational and custodial risks, and ensure accurate recordkeeping.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) The Company is in material compliance with
 all applicable laws, rules, and regulations (including those administered by the Commission,
 Commodities Futures Trading Commission, Financial Crimes Enforcement Network, OFAC and applicable
 state regulators) governing the holding, custody, transfer, and management of Crypto Assets.
 To the Company's knowledge, no part of its Crypto Assets portfolio has been used in
 material violation of applicable Money Laundering Laws, counter-terrorist financing, or economic
 Sanctions laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) The Company has not received any written
 notice from any governmental or regulatory authority asserting that its Crypto Asset activities,
 or those of the Custodian, are or have been conducted in material violation of applicable
 law. The Company accounts for its Crypto Assets in accordance with GAAP, including current
 accounting guidance, and its financial disclosures contained in the Registration Statement
 or the Prospectus reflect the nature of custodial relationships, risk of loss, and any arrangements
 that affect legal control to the extent required to be disclosed in the Registration Statement
 or the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) The Company is, and at all times, has been
 in compliance in all material respects with the Company's treasury reserve policy.

For purposes of this Agreement, "**<u>Crypto Assets</u>**" means digital assets that are issued or transferred using distributed ledger or blockchain technology, including but not limited to cryptocurrencies (e.g., Bitcoin, Ethereum), ZEC, stablecoins, and other fungible or non-fungible tokens held or used by the Company.

Any certificate signed by an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection with this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the matters set forth therein.

7. <u>Covenants of the Company</u>. The Company covenants and agrees with
 the Agent that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Registration Statement Amendments</u>.
 After the date of this Agreement and during any period in which a Prospectus relating to
 any Placement Shares is required to be delivered by the Agent under the Securities Act (including
 in circumstances where such requirement may be satisfied pursuant to Rule 172 under
 the Securities Act or similar rule), (i) the Company will notify the Agent promptly
 of the time when any subsequent amendment to the Registration Statement has been filed with
 the Commission and/or has become effective, any Rule 462(b) Registration Statement
 has been filed with the Commission or any subsequent supplement to the Prospectus has been
 filed and of any request by the Commission for any amendment or supplement to the Registration
 Statement or Prospectus or for additional information (*provided*, *however*, that
 that the Company shall not be obligated to notify the Agent of the filing of any Incorporated
 Documents which do not discuss this Agreement, the Placement or the Agent), (ii) the
 Company will prepare and file with the Commission, promptly upon the Agent's request,
 any amendments or supplements to the Registration Statement or Prospectus that, in the Agent's
 reasonable opinion, may be necessary or advisable in connection with the distribution of
 the Placement Shares by the Agent (*provided*, *however*, that the failure of the
 Agent to make such request shall not relieve the Company of any obligation or liability hereunder,
 or affect the Agent's right to rely on the representations and warranties made by the
 Company in this Agreement and *provided*, *further*, that the only remedy the Agent
 shall have with respect to the failure by the Company to make such filing shall be to cease
 making sales under this Agreement until such amendment or supplement is filed); (iii) the
 Company will not file any amendment or supplement to the Registration Statement or Prospectus
 or any Rule 462(b) Registration Statement relating to the Placement Shares or a
 security convertible into or exchangeable or exercisable for the Placement Shares unless
 a copy thereof has been submitted to the Agent within a reasonable period of time before
 the filing and the Agent has not objected thereto (*provided*, *however*, that
 the failure of the Agent to make such objection shall not relieve the Company of any obligation
 or liability hereunder, or affect the Agent's right to rely on the representations
 and warranties made by the Company in this Agreement and *provided*, *further*,
 that the only remedy the Agent shall have with respect to the failure by the Company to obtain
 such consent shall be to cease making sales under this Agreement) and the Company will furnish
 to the Agent at the time of filing thereof a copy of any Incorporated Documents, except for
 those documents available via EDGAR; and (iv) the Company will cause each amendment
 or supplement to the Prospectus to be filed with the Commission as required pursuant to the
 applicable paragraph of Rule 424(b) of the Securities Act or, in the case of Incorporated
 Documents, to be filed with the Commission as required pursuant to the Exchange Act, within
 the time period prescribed (the determination to file or not file any amendment or supplement
 with the Commission under this <u>Section 7(a)</u>, based on the Company's reasonable
 opinion or reasonable objections, shall be made exclusively by the Company).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Notice of Commission Stop Orders</u>.
 The Company will advise the Agent, promptly after it receives notice or obtains knowledge
 thereof, of the issuance or threatened issuance by the Commission of any stop order suspending
 the effectiveness of the Registration Statement or any Rule 462(b) Registration
 Statement, of the suspension of the qualification of the Placement Shares for offering or
 sale in any jurisdiction, or of the initiation or threatening of any proceeding for any such
 purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance
 of any stop order or to obtain its withdrawal if such a stop order should be issued. The
 Company will advise the Agent promptly after it receives any request by the Commission for
 any amendments to the Registration Statement or any Rule 462(b) Registration Statement
 or any amendment or supplements to the Prospectus or any Issuer Free Writing Prospectus or
 for additional information related to the offering of the Placement Shares or for additional
 information related to the Registration Statement, any Rule 462(b) Registration
 Statement, the Prospectus or any Issuer Free Writing Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Delivery of Prospectus; Subsequent Changes</u>. During any period in which a Prospectus relating to the Placement Shares is
 required to be delivered by the Agent under the Securities Act with respect to the offer
 and sale of the Placement Shares, (including in circumstances where such requirement may
 be satisfied pursuant to Rule 172 under the Securities Act or a similar rule), the Company
 will comply with all requirements imposed upon it by the Securities Act, as from time to
 time in force, and will file on or before their respective due dates all reports and any
 definitive proxy or information statements required to be filed by the Company with the Commission
 pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the
 Exchange Act. If the Company has omitted any information from the Registration Statement
 pursuant to Rule 430B under the Securities Act, it will use its best efforts to comply
 with the provisions of and make all requisite filings with the Commission pursuant to said
 Rule 430B and to notify the Agent promptly of all such filings relating to the Placement
 Shares and to notify the Agent promptly of all such filings if not available on EDGAR. If
 during such period any event occurs as a result of which the Prospectus as then amended or
 supplemented would include an untrue statement of a material fact or omit to state a material
 fact necessary to make the statements therein, in the light of the circumstances then existing,
 not misleading, or if during such period it is necessary to amend or supplement the Registration
 Statement or Prospectus to comply with the Securities Act, the Company will promptly notify
 the Agent to suspend the offering of Placement Shares during such period and the Company
 will promptly amend or supplement the Registration Statement or Prospectus (at the expense
 of the Company) so as to correct such statement or omission or effect such compliance (*provided*, *however*, that the only remedy the Agent shall have with respect to the failure by
 the Company to file such amendment or supplement to the Registration Statement or Prospectus
 shall be to cease making sales under this Agreement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Listing of Placement Shares</u>. During
 any period in which the Prospectus relating to the Placement Shares is required to be delivered
 by the Agent under the Securities Act with respect to a pending sale of the Placement Shares
 (including in circumstances where such requirement may be satisfied pursuant to Rule 172
 under the Securities Act), the Company will use its reasonable best efforts to cause the
 Placement Shares to be listed on the Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Delivery of Registration Statement and Prospectus</u>. The Company will furnish to the Agent and its counsel (at the expense
 of the Company) copies of the Registration Statement, the Prospectus (including all documents
 incorporated by reference therein) and all amendments and supplements to the Registration
 Statement or Prospectus that are filed with the Commission during any period in which a Prospectus
 relating to the Placement Shares is required to be delivered under the Securities Act (including
 all Incorporated Documents), in each case as soon as reasonably practicable and in such quantities
 as the Agent may from time to time reasonably request and, at the Agent's request,
 will also furnish copies of the Prospectus to each exchange or market on which sales of the
 Placement Shares may be made; *provided*, *however*, that the Company shall not
 be required to furnish any document (other than the Prospectus) to the Agent to the extent
 such document is available on EDGAR.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Earning Statement</u>. The Company
 will make generally available to its security holders and to the Agent as soon as practicable,
 but in any event not later than 15 months after the end of the Company's current fiscal
 quarter, an earnings statement covering a 12-month period that satisfies the provisions of
 Section 11(a) of and Rule 158 under the Securities Act (except to the extent
 posted on EDGAR).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Use of Proceeds</u>. The Company will
 use the Net Proceeds as described in the Prospectus in the section entitled "Use of
 Proceeds."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Notice of Other Sales</u>. Without
 the prior written consent of the Agent, the Company will not, directly or indirectly, offer
 to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common
 Stock (other than the Placement Shares offered pursuant to this Agreement) or securities
 convertible into or exchangeable or exercisable for Common Stock, warrants or any rights
 to purchase or acquire, Common Stock during the period beginning on the fifth (5<sup>th</sup>)
 Trading Day immediately prior to the date on which any Placement Notice is delivered to Agent
 hereunder and ending on the fifth (5<sup>th</sup>) Trading Day immediately following the
 final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice
 (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement
 Shares covered by a Placement Notice, the date of such suspension or termination); and will
 not directly or indirectly in any other "at the market", equity line of credit
 or other continuous equity transaction offer to sell, sell, contract to sell, grant any option
 to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered
 pursuant to this Agreement) or securities convertible into or exchangeable or exercisable
 for Common Stock, warrants or any rights to purchase or acquire, Common Stock prior to the
 sixtieth (60<sup>th</sup>) day immediately following the termination of this Agreement; *provided*, *however*, that such restrictions will not be required in connection with the Company's
 issuance or sale of (i) Common Stock, options to purchase Common Stock or Common Stock
 issuable upon the exercise of options, pursuant to any employee or director stock option
 or benefits plan, stock ownership plan or dividend reinvestment plan (but not Common Stock
 subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company
 whether now in effect or hereafter implemented, (ii) Common Stock issuable upon conversion
 of securities or the exercise of warrants, options or other rights in effect or outstanding,
 and disclosed in filings by the Company available on EDGAR or otherwise in writing to the
 Agent and (iii) Common Stock or securities convertible into or exchangeable for shares
 of Common Stock as consideration for mergers, acquisitions, other business combinations or
 strategic alliances occurring after the date of this Agreement which are not issued for capital
 raising purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Change of Circumstances</u>. The Company
 will, at any time during the pendency of a Placement Notice, advise the Agent promptly after
 it shall have received notice or obtained knowledge thereof, of any information or fact that
 would alter or affect in any material respect any opinion, certificate, letter or other document
 provided or required to be provided to the Agent pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Due Diligence Cooperation</u>. The
 Company will cooperate with any reasonable due diligence review conducted by the Agent or
 its representatives in connection with the transactions contemplated hereby, including, without
 limitation, providing information and making available documents and senior corporate officers,
 during regular business hours and at the Company's principal offices or via remote
 digital access, as the Agent may reasonably request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Required Filings Relating to Placement of Placement Shares</u>. The Company shall disclose, in its Quarterly Reports on Form 10-Q
 and in its Annual Report on Form 10-K to be filed by the Company with the Commission
 from time to time, the number of the Placement Shares sold through the Agent under this Agreement,
 and the net proceeds to the Company from the sale of the Placement Shares pursuant to this
 Agreement during the relevant quarter or, in the case of an Annual Report on Form 10-K,
 during the fiscal year covered by such Annual Report and the fourth quarter of such fiscal
 year, to the extent required under the Exchange Act. The Company agrees that on such dates
 as the Securities Act shall require, the Company will (i) file a prospectus supplement
 with the Commission under the applicable paragraph of Rule 424(b) under the Securities
 Act (each and every filing date under Rule 424(b), a "  **<u>Filing Date</u>** "),
 which prospectus supplement will set forth, within the relevant period, the amount of Placement
 Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable
 by the Company to the Agent with respect to such Placement Shares, and (ii) deliver
 such number of copies of each such prospectus supplement to each exchange or market on which
 such sales were effected as may be required by the rules or regulations of such exchange
 or market.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>Representation Dates; Certificate</u>.
 (1) Prior to the date of the first Placement Notice and (2) each time the Company:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) files the Prospectus relating to the Placement
 Shares or amends or supplements (other than a prospectus supplement relating solely to an
 offering of securities other than the Placement Shares) the Registration Statement or the
 Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker,
 or supplement but not by means of incorporation of documents by reference into the Registration
 Statement or the Prospectus relating to the Placement Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) files an Annual Report on Form 10-K
 under the Exchange Act (including any Annual Report on Form 10-K/A containing amended
 or restated financial information or a material amendment to the previously filed Annual
 Report on Form 10-K);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) files its Quarterly Reports on Form 10-Q
 under the Exchange Act; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) files a Current Report on Form 8-K
 containing (x) amended or restated financial information (other than information "furnished"
 pursuant to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item
 8.01 of Form 8-K relating to the reclassification of certain properties as discontinued
 operations in accordance with Statement of Financial Accounting Standards No. 144) or
 (y) disclosing any material transaction requiring the filing of historical or pro forma
 financial statements under Item 9.01 of Form 8-K and subject to the guidance set forth
 in Section 2050.3 of the Financial Reporting Manual of the Commission under the Exchange
 Act (each date of filing of one or more of the documents referred to in clauses (i) through
 (iv) shall be a "  **<u>Representation Date</u>** ");

the Company shall furnish the Agent (but in the case of clause (iv) above only if the Agent reasonably determines that the information contained in such Current Report on Form 8-K is material) with a certificate dated the Representation Date, in the form attached hereto as <u>Exhibit 7(l)</u>, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented. The requirement to provide a certificate under this <u>Section 7(l)</u> shall be waived for any Representation Date occurring at a time when no Placement Notice is outstanding or a Suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Placement Shares hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when a Suspension was in effect and did not provide the Agent with a certificate under this <u>Section 7(l)</u>, then before the Company delivers the instructions for the sale of Placement Shares or the Agent sells any Placement Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in the form attached hereto as <u>Exhibit 7(l)</u> dated as of the date that the instructions for the sale of Placement Shares are issued.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>Legal Opinion</u>. (1) Prior to
 the date of the first Placement Notice and (2) on each Representation Date with respect
 to which the Company is obligated to deliver a certificate pursuant to <u>Section 7(l)</u> for
 which no waiver is applicable and excluding the date of this Agreement, the Company shall
 cause to be furnished to the Agent (i) a written opinion and negative assurance letter
 of Morgan Lewis & Bockius LLP or other counsel reasonably satisfactory to the Agent
 and (ii) a written opinion of Foley Hoag LLP, intellectual property counsel to the Company,
 or other counsel satisfactory to the Agent, in each case in form and substance reasonably
 satisfactory to the Agent and its counsel, substantially similar to the form previously provided
 to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement
 and the Prospectus as then amended or supplemented; *provided*, that in lieu of such
 opinions for subsequent periodic filings under the Exchange Act, counsel may furnish the
 Agent with a letter (a "  **<u>Reliance Letter</u>**") to the effect that the
 Agent may rely on a prior opinion delivered under this <u>Section 7(m)</u> to the
 same extent as if it were dated the date of such letter (except that statements in such prior
 opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended
 or supplemented as of the date of the Reliance Letter).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) <u>Comfort Letter</u>. (1) Prior
 to the date of the first Placement Notice and (2) on each Representation Date with respect
 to which the Company is obligated to deliver a certificate pursuant to <u>Section 7(l)</u> for
 which no waiver is applicable and excluding the date of this Agreement, the Company shall
 cause its independent registered public accounting firm (and any other independent accountants
 whose report is included in the Registration Statement or the Prospectus) to furnish the
 Agent letters (the "  **<u>Comfort Letters</u>** "), dated the date the Comfort
 Letter is delivered, which shall meet the requirements set forth in this <u>Section 7(n)</u>.
 If requested by the Agent, the Company shall also cause a comfort letter to be furnished
 to the Agent on the date of occurrence of any material transaction or event requiring the
 filing of a Current Report on Form 8-K containing material amended financial information
 of the Company, including the restatement of the Company's financial statements. The
 Comfort Letter from the Company's independent registered public accounting firm shall
 be in a form and substance satisfactory to the Agent, (i) confirming that they are an
 independent registered public accounting firm within the meaning of the Securities Act and
 the Public Company Accounting Oversight Board ("  **<u>PCAOB</u>** "), (ii) stating,
 as of such date, the conclusions and findings of such firm with respect to the financial
 information and other matters ordinarily covered by accountants' "comfort letters"
 to underwriters in connection with registered public offerings (the first such letter, the
 "  **<u>Initial Comfort Letter</u>**") and (iii) updating the Initial Comfort
 Letter with any information that would have been included in the Initial Comfort Letter had
 it been given on such date and modified as necessary to relate to the Registration Statement
 and the Prospectus, as amended and supplemented to the date of such letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) <u>Market Activities; Compliance with Regulation M</u>. The Company will not, directly or indirectly, (i) take any action
 designed to cause or result in, or that constitutes or would reasonably be expected to constitute,
 the stabilization or manipulation of the price of any security of the Company to facilitate
 the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock in
 violation of Regulation M, or pay anyone any compensation for soliciting purchases of the
 Placement Shares other than the Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) <u>Investment Company Act</u>. The Company
 will conduct its affairs in such a manner so as to reasonably ensure that neither it nor
 any of its Subsidiaries will be or become, at any time prior to the termination of this Agreement,
 an "investment company," as such term is defined in the Investment Company Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) <u>Securities Act and Exchange Act Compliance</u>.
 The Company will use its best efforts to comply with all requirements imposed upon it by
 the Securities Act and the Exchange Act as from time to time in force, so far as necessary
 to permit the sales of, or dealings in, the Placement Shares as contemplated by the provisions
 hereof and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) <u>No Offer to Sell</u>. Other than an
 Issuer Free Writing Prospectus approved in advance by the Company and the Agent in its capacity
 as agent hereunder, neither the Agent nor the Company (including its agents and representatives,
 other than the Agent in its capacity as such) will make, use, prepare, authorize, approve
 or refer to any written communication (as defined in Rule 405 under the Securities Act),
 required to be filed with the Commission, that constitutes an offer to sell or solicitation
 of an offer to buy Placement Shares hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) <u>Blue Sky and Other Qualifications</u> *.* The Company will use its commercially reasonable efforts, in cooperation with the Agent,
 to qualify the Placement Shares for offering and sale, or to obtain an exemption for the
 Placement Shares to be offered and sold, under the applicable securities laws of such states
 and other jurisdictions (domestic or foreign) as the Agent may designate and to maintain
 such qualifications and exemptions in effect for so long as required for the distribution
 of the Placement Shares (but in no event for less than one year from the date of this Agreement); *provided*, *however*, that the Company shall not be obligated to file any general
 consent to service of process or to qualify as a foreign corporation or as a dealer in securities
 in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect
 of doing business in any jurisdiction in which it is not otherwise so subject. In each jurisdiction
 in which the Placement Shares have been so qualified or exempt, the Company will file such
 statements and reports as may be required by the laws of such jurisdiction to continue such
 qualification or exemption, as the case may be, in effect for so long as required for the
 distribution of the Placement Shares (but in no event for less than one year from the date
 of this Agreement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) <u>Sarbanes-Oxley Act</u>. The Company
 and the Subsidiaries will maintain and keep accurate books and records reflecting their assets
 and maintain internal accounting controls in a manner designed to provide reasonable assurance
 regarding the reliability of financial reporting and the preparation of financial statements
 for external purposes in accordance with GAAP and including those policies and procedures
 that (i) pertain to the maintenance of records that in reasonable detail accurately
 and fairly reflect the transactions and dispositions of the assets of the Company, (ii) provide
 reasonable assurance that transactions are recorded as necessary to permit the preparation
 of the Company's consolidated financial statements in accordance with GAAP, (iii) that
 receipts and expenditures of the Company are being made only in accordance with management's
 and the Company's directors' authorization, and (iv) provide reasonable
 assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition
 of the Company's assets that could have a material effect on its financial statements.
 The Company and the Subsidiaries will maintain such controls and other procedures, including,
 without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and
 the applicable regulations thereunder that are designed to ensure that information required
 to be disclosed by the Company in the reports that it files or submits under the Exchange
 Act is recorded, processed, summarized and reported, within the time periods specified in
 the Commission's rules and forms, including, without limitation, controls and
 procedures designed to ensure that information required to be disclosed by the Company in
 the reports that it files or submits under the Exchange Act is accumulated and communicated
 to the Company's management, including its principal executive officer and principal
 financial officer, or persons performing similar functions, as appropriate to allow timely
 decisions regarding required disclosure and to ensure that material information relating
 to the Company or the Subsidiaries is made known to them by others within those entities,
 particularly during the period in which such periodic reports are being prepared.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) <u>Secretary's Certificate; Regulatory Certificate; Further Documentation</u>. Prior to the date of the first Placement Notice,
 the Company shall deliver to the Agent (1) a certificate of the Secretary of the Company
 and attested to by an executive officer of the Company, dated as of such date, certifying
 as to (i) the Certificate of Incorporation of the Company, (ii) the By-laws of
 the Company, (iii) the resolutions of the Board of Directors of the Company and any
 other authorized committee authorizing the execution, delivery and performance of this Agreement
 and the issuance of the Placement Shares and (iv) the incumbency of the officers duly
 authorized to execute this Agreement and the other documents contemplated by this Agreement
 and (2) an officer's certificate, as of such date, certifying as to certain regulatory
 disclosures included in the Company's filings with the Commission. Within five (5) Trading
 Days of each Representation Date, the Company shall have furnished to the Agent such further
 information, certificates and documents as the Agent may reasonably request.

8. <u>Payment of Expenses</u>. The Company will pay all expenses incident
 to the performance of its obligations under this Agreement, including (i) the preparation and filing
 of the Registration Statement, including any fees required by the Commission, and the printing or electronic
 delivery of the Prospectus as originally filed and of each amendment and supplement thereto relating
 to the Placement Shares, in such number as the Agent shall deem necessary, (ii) the printing and
 delivery to the Agent of this Agreement and such other documents as may be required in connection with
 the offering, purchase, sale, issuance or delivery of the Placement Shares, (iii) the preparation,
 issuance and delivery of the certificates, if any, for the Placement Shares to the Agent, including any
 stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes payable upon
 the sale, issuance or delivery of the Placement Shares to the Agent, (iv) the fees and disbursements
 of the counsel, accountants and other advisors to the Company, (v) the reasonable and documented
 fees and expenses of Agent including but not limited to the fees and expenses of the counsel to the Agent,
 payable upon the execution of this Agreement, (a) in an amount not to exceed $100,000 in connection
 with the execution of this Agreement, (b) in an amount not to exceed $25,000 for each Representation
 Date in connection with the filing of a Quarterly Report on Form 10-Q and in an amount not to exceed
 $25,000 for each Representation Date in connection with the filing of an Annual Report on Form 10-K,
 payable thereafter in connection with each such Representation Date with respect to which the Company
 is obligated to deliver a certificate pursuant to <u>Section 7(l)</u> for which no waiver is
 applicable and excluding the date of this Agreement, and (c) in an amount not to exceed $40,000
 for each program "refresh" (filing of a new registration statement, prospectus or prospectus
 supplement relating to the Placement Shares and/or an amendment of this Agreement) executed pursuant
 to this Agreement, (vi) the qualification or exemption of the Placement Shares under state securities
 laws in accordance with the provisions of <u>Section 7(r)</u> hereof, including filing fees,
 but excluding fees of the Agent's counsel, (vii) the printing and delivery to the Agent of
 copies of any Permitted Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements
 thereto relating to the Placement Shares in such number as the Agent shall deem necessary, (viii) the
 preparation, printing and delivery to the Agent of copies of the blue sky survey, (ix) the fees
 and expenses of the transfer agent and registrar for the Common Stock, (x) the filing and other
 fees incident to any review by FINRA of the terms of the sale of the Placement Shares including the reasonable
 and documented fees of the Agent's counsel (subject to the cap, set forth in clause (v) above),
 and (xi) the fees and expenses incurred in connection with the listing of the Placement Shares on
 the Exchange. The Company agrees to pay the reasonable and documented fees and expenses of counsel to
 the Agent set forth in clause (v) above by wire transfer of immediately available funds directly
 to such counsel upon presentation of an invoice containing the requisite payment information prepared
 by such counsel, and such counsel shall be a third-party beneficiary of the expense reimbursement obligations
 set forth in this <u>Section 8</u>.

9. <u>Conditions to Agent's Obligations</u>. The obligations of the
 Agent hereunder with respect to a Placement will be subject to the continuing accuracy and completeness
 of the representations and warranties made by the Company herein, to the due performance by the Company
 of its obligations hereunder, to the completion by the Agent of a due diligence review satisfactory to
 it in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole
 discretion) of the following additional conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Registration Statement Effective</u>.
 The Registration Statement shall be effective and shall be available for the (i) resale
 of all Placement Shares issued to the Agent and not yet sold by the Agent and (ii) sale
 of all Placement Shares contemplated to be issued by any Placement Notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>No Material Notices</u>. None of the
 following events shall have occurred and be continuing: (i) receipt by the Company of
 any request for additional information from the Commission or any other federal or state
 Governmental Authority during the period of effectiveness of the Registration Statement,
 the response to which would require any post-effective amendments or supplements to the Registration
 Statement or the Prospectus; (ii) the issuance by the Commission or any other federal
 or state Governmental Authority of any stop order suspending the effectiveness of the Registration
 Statement or the initiation of any proceedings for that purpose; (iii) receipt by the
 Company of any notification with respect to the suspension of the qualification or exemption
 from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation
 or threatening of any proceeding for such purpose; or (iv) the occurrence of any event
 that makes any statement of a material fact made in the Registration Statement or the Prospectus
 or any document incorporated or deemed to be incorporated therein by reference untrue or
 that requires the making of any changes in the Registration Statement, the Prospectus or
 documents so that, in the case of the Registration Statement, it will not contain an untrue
 statement of a material fact or omit to state any material fact required to be stated therein
 or necessary to make the statements therein not misleading and, that in the case of the Prospectus,
 it will not contain an untrue statement of a material fact or omit to state a material fact
 required to be stated therein or necessary to make the statements therein, in the light of
 the circumstances under which they were made, not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>No Misstatement or Material Omission</u>.
 The Agent shall not have advised the Company that the Registration Statement or Prospectus,
 or any amendment or supplement thereto, contains an untrue statement of fact that in the
 Agent's reasonable opinion is material, or omits to state a fact that in the Agent's
 reasonable opinion is material and is required to be stated therein or is necessary to make
 the statements therein not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Material Changes</u>. Except as contemplated
 in the Registration Statement or Prospectus, or disclosed in the Company's reports
 filed with the Commission, there shall not have been any material adverse change in the authorized
 capital stock of the Company or any Material Adverse Effect or any development that would
 cause a Material Adverse Effect, or a downgrading in or withdrawal of the rating assigned
 to any of the Company's securities (other than asset backed securities) by any rating
 organization or a public announcement by any rating organization that it has under surveillance
 or review its rating of any of the Company's securities (other than asset backed securities),
 the effect of which, in the case of any such action by a rating organization described above,
 in the reasonable judgment of the Agent (without relieving the Company of any obligation
 or liability it may otherwise have), is so material as to make it impracticable or inadvisable
 to proceed with the offering of the Placement Shares on the terms and in the manner contemplated
 in the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Legal Opinions</u>. The Agent shall
 have received the opinions or Reliance Letters and negative assurance letters required to
 be delivered pursuant to <u>Section 7(m)</u> on or before the date on which such
 delivery of such opinions or Reliance Letter and negative assurance letter, as applicable,
 is required pursuant to <u>Section 7(m)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Comfort Letter</u>. The Agent shall
 have received the Comfort Letter required to be delivered pursuant to <u>Section 7(n)</u> on
 or before the date on which such delivery of such Comfort Letter is required pursuant to <u>Section 7(n)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Representation Certificate</u>. The
 Agent shall have received the certificate required to be delivered pursuant to <u>Section 7(l)</u> on
 or before the date on which delivery of such certificate is required pursuant to <u>Section 7(l)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>No Suspension</u>. Trading in the Common
 Stock shall not have been suspended on the Exchange and the Common Stock shall not have been
 delisted from the Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Other Materials</u>. On each date on
 which the Company is required to deliver a certificate pursuant to <u>Section 7(l)</u>,
 the Company shall have furnished to the Agent such appropriate further information, opinions,
 certificates, letters and other documents as the Agent may reasonably request. All such opinions,
 certificates, letters and other documents will be in compliance with the provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Securities Act Filings Made</u>. All
 filings with the Commission required by Rule 424 or Rule 433 under the Securities
 Act to have been filed prior to the issuance of any Placement Notice hereunder shall have
 been made within the applicable time period prescribed for such filing by Rule 424 or
 Rule 433, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Approval for Listing</u>. The Placement
 Shares shall either have been (i) approved for listing on the Exchange, subject only
 to notice of issuance, or (ii) the Company shall have filed an application for listing
 of the Placement Shares on the Exchange at, or prior to, the issuance of any Placement Notice
 and the Exchange shall have reviewed such application and not provided any objections thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>FINRA</u>. If applicable, FINRA shall
 have raised no objection to the terms of this offering and the amount of compensation allowable
 or payable to the Agent as described in the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>No Termination Event</u>. There shall
 not have occurred any event that would permit the Agent to terminate this Agreement pursuant
 to <u>Section 12(a)</u>.

10. <u>Indemnification and Contribution</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Company Indemnification</u>. The Company
 agrees to indemnify and hold harmless the Agent, its affiliates and their respective partners,
 members, directors, officers, employees and agents and each person, if any, who controls
 the Agent or any affiliate within the meaning of Section 15 of the Securities Act or
 Section 20 of the Exchange Act as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) against any and all loss, liability, claim,
 damage and reasonable and documented expense whatsoever, as incurred, joint or several, arising
 out of or based upon any untrue statement or alleged untrue statement of a material fact
 contained in the Registration Statement (or any amendment thereto), or the omission or alleged
 omission therefrom of a material fact required to be stated therein or necessary to make
 the statements therein not misleading, or arising out of any untrue statement or alleged
 untrue statement of a material fact included in any related Issuer Free Writing Prospectus
 or the Prospectus (or any amendment or supplement thereto), the omission or alleged omission
 therefrom of a material fact necessary in order to make the statements therein, in light
 of the circumstances under which they were made, not misleading, or any breach by the Company
 of any of its respective representations, warranties or agreements contained in this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) against any and all loss, liability, claim,
 damage and reasonable and documented expense whatsoever, as incurred, joint or several, to
 the extent of the aggregate amount paid in settlement of any litigation, or any investigation
 or proceeding by any Governmental Authority, commenced or threatened, or of any claim whatsoever
 based upon any such untrue statement or omission, or any such alleged untrue statement or
 omission; *provided* that (subject to <u>Section 10(d)</u> below) any such
 settlement is effected with the written consent of the Company, which consent shall not unreasonably
 be delayed or withheld; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) against any and all expense whatsoever,
 as incurred (including the reasonable and documented out-of-pocket fees and disbursements
 of counsel), reasonably incurred in investigating, preparing or defending against any litigation,
 or any investigation or proceeding by any Governmental Authority, commenced or threatened,
 or any claim whatsoever based upon any such untrue statement or omission, or any such alleged
 untrue statement or omission (whether or not a party), to the extent that any such expense
 is not paid under (i) or (ii) above,

*provided*, *however*, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with the Agent Information (as defined below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Agent Indemnification</u>. Agent agrees
 to indemnify and hold harmless the Company and its directors and each officer of the Company
 who signed the Registration Statement, and each person, if any, who controls the Company
 within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
 Act against any and all loss, liability, claim, damage and expense described in the indemnity
 contained in <u>Section 10(a)</u>, as incurred, but only with respect to untrue statements
 or omissions, or alleged untrue statements or omissions, made in the Registration Statement
 (or any amendments thereto), the Prospectus (or any amendment or supplement thereto) or any
 Issuer Free Writing Prospectus (or any amendment or supplement thereto) in reliance upon
 and in conformity with information relating to the Agent and furnished to the Company in
 writing by the Agent expressly for use therein. The Company hereby acknowledges that the
 only information that the Agent has furnished to the Company expressly for use in the Registration
 Statement, the Prospectus or any Issuer Free Writing Prospectus (or any amendment or supplement
 thereto) are the statements set forth in the first sentence of the seventh paragraph under
 the caption "Plan of Distribution" in the Prospectus (the "  **<u>Agent Information</u>** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Procedure</u>. Any party that proposes
 to assert the right to be indemnified under this <u>Section 10</u> will, promptly after
 receipt of notice of commencement of any action against such party in respect of which a
 claim is to be made against an indemnifying party or parties under this <u>Section 10</u>,
 notify each such indemnifying party of the commencement of such action, enclosing a copy
 of all papers served, but the omission so to notify such indemnifying party will not relieve
 the indemnifying party from (i) any liability that it might have to any indemnified
 party otherwise than under this <u>Section 10</u> and (ii) any liability that it
 may have to any indemnified party under the foregoing provision of this <u>Section 10</u> unless, and only to the extent that, such omission results in the forfeiture of substantive
 rights or defenses by the indemnifying party. If any such action is brought against any indemnified
 party and it notifies the indemnifying party of its commencement, the indemnifying party
 will be entitled to participate in and, to the extent that it elects by delivering written
 notice to the indemnified party promptly after receiving notice of the commencement of the
 action from the indemnified party, jointly with any other indemnifying party similarly notified,
 to assume the defense of the action, with counsel reasonably satisfactory to the indemnified
 party, and after notice from the indemnifying party to the indemnified party of its election
 to assume the defense, the indemnifying party will not be liable to the indemnified party
 for any other legal expenses except as provided below and except for the reasonable costs
 of investigation subsequently incurred by the indemnified party in connection with the defense.
 The indemnified party will have the right to employ its own counsel in any such action, but
 the fees, expenses and other charges of such counsel will be at the expense of such indemnified
 party unless (1) the employment of counsel by the indemnified party has been authorized
 in writing by the indemnifying party, (2) the indemnified party has reasonably concluded
 (based on advice of counsel) that there may be legal defenses available to it or other indemnified
 parties that are different from or in addition to those available to the indemnifying party,
 (3) a conflict or potential conflict exists (based on advice of counsel to the indemnified
 party) between the indemnified party and the indemnifying party (in which case the indemnifying
 party will not have the right to direct the defense of such action on behalf of the indemnified
 party) or (4) the indemnifying party has not in fact employed counsel to assume the
 defense of such action or counsel reasonably satisfactory to the indemnified party, in each
 case, within a reasonable time after receiving notice of the commencement of the action;
 in each of which cases the reasonable fees, disbursements and other charges of counsel will
 be at the expense of the indemnifying party or parties. It is understood that the indemnifying
 party or parties shall not, in connection with any proceeding or related proceedings in the
 same jurisdiction, be liable for the reasonable fees, disbursements and other charges of
 more than one separate firm (plus local counsel) admitted to practice in such jurisdiction
 at any one time for all such indemnified party or parties. All such fees, disbursements and
 other charges will be reimbursed by the indemnifying party promptly as they are incurred.
 An indemnifying party will not, in any event, be liable for any settlement of any action
 or claim effected without its written consent. No indemnifying party shall, without the prior
 written consent of each indemnified party, settle or compromise or consent to the entry of
 any judgment in any pending or threatened claim, action or proceeding relating to the matters
 contemplated by this <u>Section 10</u> (whether or not any indemnified party is a party
 thereto), unless such settlement, compromise or consent (1) includes an express and
 unconditional release of each indemnified party, in form and substance reasonably satisfactory
 to such indemnified party, from all liability arising out of such litigation, investigation,
 proceeding or claim and (2) does not include a statement as to or an admission of fault,
 culpability or a failure to act by or on behalf of any indemnified party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Settlement Without Consent if Failure to Reimburse</u> *.* If an indemnified party shall have requested an indemnifying party
 to reimburse the indemnified party for reasonable fees and expenses of counsel, such indemnifying
 party agrees that it shall be liable for any settlement of the nature contemplated by <u>Section 10(a)(ii)</u> effected
 without its written consent if (1) such settlement is entered into more than 45 days
 after receipt by such indemnifying party of the aforesaid request, (2) such indemnifying
 party shall have received notice of the terms of such settlement at least 30 days prior to
 such settlement being entered into and (3) such indemnifying party shall not have reimbursed
 such indemnified party in accordance with such request prior to the date of such settlement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Contribution</u>. In order to provide
 for just and equitable contribution in circumstances in which the indemnification provided
 for in the foregoing paragraphs of this <u>Section 10</u> is applicable in accordance
 with its terms but for any reason is held to be unavailable or insufficient from the Company
 or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities,
 expenses and damages (including any investigative, legal and other expenses reasonably incurred
 in connection with, and any amount paid in settlement of, any action, suit or proceeding
 or any claim asserted) to which the Company and the Agent may be subject in such proportion
 as shall be appropriate to reflect the relative benefits received by the Company on the one
 hand and the Agent on the other hand. The relative benefits received by the Company on the
 one hand and the Agent on the other hand shall be deemed to be in the same proportion as
 the total net proceeds from the sale of the Placement Shares (before deducting expenses)
 received by the Company bear to the total compensation received by the Agent from the sale
 of Placement Shares on behalf of the Company. If, but only if, the allocation provided by
 the foregoing sentence is not permitted by applicable law, the allocation of contribution
 shall be made in such proportion as is appropriate to reflect not only the relative benefits
 referred to in the foregoing sentence but also the relative fault of the Company, on the
 one hand, and the Agent, on the other hand, with respect to the statements or omission that
 resulted in such loss, claim, liability, expense or damage, or action in respect thereof,
 as well as any other relevant equitable considerations with respect to such offering. Such
 relative fault shall be determined by reference to, among other things, whether the untrue
 or alleged untrue statement of a material fact or omission or alleged omission to state a
 material fact relates to information supplied by the Company or the Agent, the intent of
 the parties and their relative knowledge, access to information and opportunity to correct
 or prevent such statement or omission. The Company and the Agent agree that it would not
 be just and equitable if contributions pursuant to this <u>Section 10(e)</u> were
 to be determined by pro rata allocation or by any other method of allocation that does not
 take into account the equitable considerations referred to herein. The amount paid or payable
 by an indemnified party as a result of the loss, claim, liability, expense, or damage, or
 action in respect thereof, referred to above in this <u>Section 10(e)</u> shall
 be deemed to include, for the purpose of this <u>Section 10(e)</u>, any legal or other
 expenses reasonably incurred by such indemnified party in connection with investigating or
 defending any such action or claim to the extent consistent with <u>Section 10(c)</u> hereof.
 Notwithstanding the foregoing provisions of this <u>Section 10(e)</u>, the Agent shall
 not be required to contribute any amount in excess of the commissions received by it under
 this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning
 of Section 11(f) of the Securities Act) will be entitled to contribution from any
 person who was not guilty of such fraudulent misrepresentation. For purposes of this <u>Section 10(e)</u>,
 any person who controls a party to this Agreement within the meaning of the Securities Act,
 any affiliates of the Agent and any officers, directors, partners, employees or agents of
 the Agent or any of its affiliates, will have the same rights to contribution as that party,
 and each director of the Company and each officer of the Company who signed the Registration
 Statement will have the same rights to contribution as the Company, subject in each case
 to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice
 of commencement of any action against such party in respect of which a claim for contribution
 may be made under this <u>Section 10(e)</u>, will notify any such party or parties from
 whom contribution may be sought, but the omission to so notify will not relieve that party
 or parties from whom contribution may be sought from any other obligation it or they may
 have under this <u>Section 10(e)</u> except to the extent that the failure to so
 notify such other party materially prejudiced the substantive rights or defenses of the party
 from whom contribution is sought. Except for a settlement entered into pursuant to the last
 sentence of <u>Section 10(c)</u> hereof, no party will be liable for contribution
 with respect to any action or claim settled without its written consent if such consent is
 required pursuant to <u>Section 10(c)</u> hereof.

11. <u>Representations and Agreements to Survive Delivery</u>. The indemnity
 and contribution agreements contained in <u>Section 10</u> of this Agreement and all representations
 and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as
 of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent,
 any controlling persons, or the Company (or any of their respective officers, directors, employees or
 controlling persons), (ii) delivery and acceptance of the Placement Shares and payment therefor
 or (iii) any termination of this Agreement.

12. <u>Termination</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Agent may terminate this Agreement,
 by notice to the Company, as hereinafter specified at any time (1) if any Material Adverse
 Effect, or any development that could reasonably be expected to result in a Material Adverse
 Effect, has occurred, which individually or in the aggregate, in the sole judgment of the
 Agent makes it impractical or inadvisable to market the Placement Shares or to enforce contracts
 for the sale of the Placement Shares, (2) the Company shall have failed, refused or
 been unable to perform any agreement on its part to be performed hereunder (3) if there
 has occurred any material adverse change in the financial markets in the United States or
 the international financial markets, any outbreak of hostilities or escalation thereof or
 other calamity or crisis or any change or development involving a prospective change in national
 or international political, financial or economic conditions, in each case the effect of
 which is such as to make it, in the judgment of the Agent, impracticable or inadvisable to
 market the Placement Shares or to enforce contracts for the sale of the Placement Shares,
 (4) if trading in the Common Stock has been suspended or limited by the Commission or
 the Exchange, or if trading generally on the Exchange has been suspended or limited, or minimum
 prices for trading have been fixed on the Exchange, (5) if any suspension of trading
 of any securities of the Company on any exchange or in the over-the-counter market shall
 have occurred and be continuing, (6) if a major disruption of securities settlements
 or clearance services in the United States shall have occurred and be continuing, or (7) if
 a banking moratorium has been declared by either U.S. Federal or New York authorities. Any
 such termination shall be without liability of any party to any other party except that the
 provisions of <u>Section 8</u> (Payment of Expenses), <u>Section 10</u> (Indemnification
 and Contribution), <u>Section 11</u> (Representations and Agreements to Survive Delivery), <u>Section 17</u> (Governing Law and Time; Waiver of Jury Trial) and <u>Section 18</u> (Consent to Jurisdiction) hereof shall remain in full force and effect notwithstanding such
 termination. If the Agent elects to terminate this Agreement as provided in this <u>Section 12(a)</u>,
 the Agent shall provide the required notice as specified in <u>Section 13</u> (Notices).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company shall have the right, by giving
 ten (10) Business Days' notice as hereinafter specified to terminate this Agreement
 in its sole discretion at any time after the date of this Agreement. Any such termination
 shall be without liability of any party to any other party except that the provisions of <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u> and <u>Section 18</u> hereof shall remain in full force and effect notwithstanding such
 termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Agent shall have the right, by giving
 ten (10) Business Days' notice as hereinafter specified to terminate this Agreement
 in its sole discretion at any time after the date of this Agreement. Any such termination
 shall be without liability of any party to any other party except that the provisions of <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u> and <u>Section 18</u> hereof shall remain in full force and effect notwithstanding such
 termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) This Agreement shall remain in full force
 and effect unless terminated pursuant to <u>Sections 12(a)</u>, <u>(b)</u>, or <u>(c)</u> above
 or otherwise by mutual agreement of the parties; *provided*, *however*, that any
 such termination by mutual agreement shall in all cases be deemed to provide that <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u> and <u>Section 18</u> shall remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Any termination of this Agreement shall
 be effective on the date specified in such notice of termination; *provided*, *however*,
 that such termination shall not be effective until the close of business on the date of receipt
 of such notice by the Agent or the Company, as the case may be. If such termination shall
 occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares
 shall settle in accordance with the provisions of this Agreement.

13. <u>Notices</u>. All notices or other communications required or permitted
 to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing,
 unless otherwise specified, and if sent to the Agent, shall be delivered to:

---

| |
|:---|
| Cantor Fitzgerald & Co. |
| 499 Park Avenue |
| New York, NY 10022 |
| Attention: Capital Markets |
| Email:CFCEO@cantor.com |

---

and:

---

| |
|:---|
| Cantor Fitzgerald & Co. |
| 499 Park Avenue |
| New York, NY 10022 |
| Attention: General Counsel |
| Email: legal-IBD@cantor.com |

---

with a copy to:

---

| |
|:---|
| Paul Hastings LLP |
| 1117 California Avenue |
| Palo Alto, CA 94304 |
| Attention: Jeff Hartlin |
| E-mail: jeffhartlin@paulhastings.com |

---

and if to the Company, shall be delivered to:

---

| |
|:---|
| Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.) |
| 47 Thorndike St. Suite B1-1 |
| Cambridge, MA 02141 |
| Attention: Douglas E. Onsi |
| E-mail: donsi@leaptx.com |

---

with a copy to:

---

| | |
|:---|:---|
| Morgan Lewis & Bockius LLP | Morgan Lewis & Bockius LLP |
| One Federal Street | One Federal Street |
| Boston, MA 02110 | Boston, MA 02110 |
| Attention: | Julio Vega |
|  | Rahul K. Patel |
| E-mail: | julio.vega@morganlewis.com |
|  | rahul.patel@morganlewis.com |

---

Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) by Electronic Notice, as set forth below, (iii) on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iv) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, "**<u>Business Day</u>**" shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.

An electronic communication ("**<u>Electronic Notice</u>**") shall be deemed written notice for purposes of this <u>Section 13</u> if sent to the electronic mail address specified by the receiving party herein or under separate cover. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form ("**<u>Nonelectronic Notic</u>e**") which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice, provided that any failure to provide such Nonelectronic Notice within such time period shall not affect the effectiveness or timing thereof of the Electronic Notice.

14. <u>Successors and Assigns</u>. This Agreement shall inure to the benefit
 of and be binding upon the Company and the Agent and their respective successors and the parties referred
 to in <u>Section 10</u> hereof. References to any of the parties contained in this Agreement shall
 be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement,
 express or implied, is intended to confer upon any party other than the parties hereto or their respective
 successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason
 of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights
 or obligations under this Agreement without the prior written consent of the other party; *provided*, *however*, that the Agent may assign its rights and obligations hereunder to an affiliate thereof
 without obtaining the Company's consent, so long as such affiliate is a registered broker dealer.

15. <u>Adjustments for Stock Splits</u>. The parties acknowledge and agree
 that all share-related numbers contained in this Agreement shall be adjusted to take into account any
 stock split, stock dividend or similar event effected with respect to the Placement Shares.

16. <u>Entire Agreement; Amendment; Severability; Waiver</u>. This Agreement
 (including all schedules and exhibits attached hereto and Placement Notices issued pursuant hereto)
 constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
 both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this
 Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the
 Company and the Agent. In the event that any one or more of the provisions contained herein, or the
 application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court
 of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible
 extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein
 shall be construed as if such invalid, illegal or unenforceable term or provision was not contained
 herein, but only to the extent that giving effect to such provision and the remainder of the terms and
 provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.
 No implied waiver by a party shall arise in the absence of a waiver in writing signed by such party.
 No failure or delay in exercising any right, power, or privilege hereunder shall operate as a waiver
 thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof
 or the exercise of any right, power, or privilege hereunder.

17.  **<u>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</u>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.** 

18.  **<u>CONSENT TO JURISDICTION</u>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.** 

19. <u>Counterparts</u>. This Agreement may be executed in two or more counterparts,
 each of which shall be deemed an original, but all of which together shall constitute one and the same
 instrument. Delivery of an executed Agreement by one party to the other may be made by electronic mail
 (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic
 Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com)
 or other transmission method and any counterpart so delivered shall be deemed to have been duly and
 validly delivered and be valid and effective for all purposes.

20. <u>Construction</u>. The section and exhibit headings herein are for
 convenience only and shall not affect the construction hereof. References herein to any law, statute,
 ordinance, code, regulation, rule or other requirement of any Governmental Authority shall be deemed
 to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any Governmental
 Authority as amended, reenacted, supplemented or superseded in whole or in part and in effect from time
 to time and also to all rules and regulations promulgated thereunder.

21. <u>Permitted Free Writing Prospectuses</u>. The Company represents,
 warrants and agrees that, unless it obtains the prior written consent of the Agent (including by email
 correspondence to each of the individuals of such party set forth on <u>Schedule 3</u>, if receipt of
 such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other
 than via auto-reply) such consent not to be unreasonably withheld, conditioned or delayed, and the Agent
 represents, warrants and agrees that, unless it obtains the prior written consent of the Company (including
 by email correspondence to each of the individuals of such party set forth on <u>Schedule 3</u>, if
 receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice
 is sent, other than via auto-reply), it has not made and will not make any offer relating to the Placement
 Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute a
 "free writing prospectus," as defined in Rule 405, required to be filed with the Commission.
 Any such free writing prospectus consented to by the Agent or by the Company, as the case may be, is
 hereinafter referred to as a "Permitted Free Writing Prospectus." The Company represents
 and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus
 as an "issuer free writing prospectus," as defined in Rule 433, and has complied and
 will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus,
 including timely filing with the Commission where required, legending and record keeping. For the purposes
 of clarity, the parties hereto agree that all free writing prospectuses, if any, listed in <u>Exhibit 21</u> hereto are Permitted Free Writing Prospectuses.

22. <u>Absence of Fiduciary Relationship</u>. The Company acknowledges and
 agrees that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Agent is acting solely as agent in
 connection with the public offering of the Placement Shares and in connection with each transaction
 contemplated by this Agreement and the process leading to such transactions, and no fiduciary
 or advisory relationship between the Company or any of its respective affiliates, stockholders
 (or other equity holders), creditors or employees or any other party, on the one hand, and
 the Agent, on the other hand, has been or will be created in respect of any of the transactions
 contemplated by this Agreement, irrespective of whether or not the Agent has advised or is
 advising the Company on other matters, and the Agent has no obligation to the Company with
 respect to the transactions contemplated by this Agreement except the obligations expressly
 set forth in this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) it is capable of evaluating and understanding,
 and understands and accepts, the terms, risks and conditions of the transactions contemplated
 by this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) neither the Agent nor its affiliates have
 provided any legal, accounting, regulatory or tax advice with respect to the transactions
 contemplated by this Agreement and it has consulted its own legal, accounting, regulatory
 and tax advisors to the extent it has deemed appropriate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) it is aware that the Agent and its affiliates
 are engaged in a broad range of transactions which may involve interests that differ from
 those of the Company and the Agent and its affiliates have no obligation to disclose such
 interests and transactions to the Company by virtue of any fiduciary, advisory or agency
 relationship or otherwise; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) it waives, to the fullest extent permitted
 by law, any claims it may have against the Agent or its affiliates for breach of fiduciary
 duty or alleged breach of fiduciary duty in connection with the sale of Placement Shares
 under this Agreement and agrees that the Agent and its affiliates shall not have any liability
 (whether direct or indirect, in contract, tort or otherwise) to the Company in respect of
 such a fiduciary duty claim or to any person asserting a fiduciary duty claim on the Company's
 behalf or in right of the Company or any employees or creditors of Company.

23. <u>Definitions</u>. As used in this Agreement, the following terms have
 the respective meanings set forth below:

"**<u>Applicable Time</u>**" means (i) each Representation Date, (ii) the time of each sale of any Placement Shares pursuant to this Agreement and (iii) each Settlement Date.

"**<u>Governmental Authority</u>**" means (i) any federal, provincial, state, local, municipal, national or international government or governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral body (public or private); (ii) any self-regulatory organization; or (iii) any political subdivision of any of the foregoing.

"**<u>Issuer Free Writing Prospectus</u>**" means any "issuer free writing prospectus," as defined in Rule 433, relating to the Placement Shares that (1) is required to be filed with the Commission by the Company, (2) is a "road show" that is a "written communication" within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g) under the Securities Act.

"**<u>Rule 164</u>**," "**<u>Rule 172</u>**," "**<u>Rule 405</u>**," "**<u>Rule 415</u>**," "**<u>Rule 424</u>**," "**<u>Rule 424(b)</u>**," "**<u>Rule 430B</u>**," and "**<u>Rule 433</u>**" refer to such rules under the Securities Act.

**[*Signature Page Follows*]**

If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this Agreement shall constitute a binding agreement between the Company and the Agent.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| CYPHERPUNK TECHNOLOGIES INC. (F/K/A LEAP THERAPEUTICS, INC.) | CYPHERPUNK TECHNOLOGIES INC. (F/K/A LEAP THERAPEUTICS, INC.) |
| By: | /s/ Douglas E. Onsi |
|  | Name: Douglas E. Onsi |
|  | Title: President & CEO |

---

---

| | |
|:---|:---|
| ACCEPTED as of the date first-above written: | ACCEPTED as of the date first-above written: |
| CANTOR FITZGERALD & CO. | CANTOR FITZGERALD & CO. |
| By: | /s/ Sameer Vasudev |
|  | Name: Sameer Vasudev |
|  | Title: Managing Director |

---

**SCHEDULE 1**

**Form of Placement Notice**

From: CYPHERPUNK TECHNOLOGIES INC. (F/K/A LEAP THERAPEUTICS, INC.)

To: Cantor Fitzgerald & Co.<br> Attention: [·]

Subject: Placement Notice

Date: [·], 2025

Ladies and Gentlemen:

Pursuant to the terms and subject to the conditions contained in the Sales Agreement between Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.), a Delaware corporation (the "**<u>Company</u>**"), and Cantor Fitzgerald & Co. ("**<u>Agent</u>**"), dated November 12, 2025, the Company hereby requests that the Agent sell up to [•] shares of the Company's common stock, par value $0.001 per share, at a minimum market price of $[•] per share, during the time period beginning [month, day, time] and ending [month, day, time].

**SCHEDULE 2**

**Compensation**

The Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount up to 3.0% of the aggregate gross proceeds from each sale of Placement Shares.

**SCHEDULE 3**

**Notice Parties**

<u>The Company</u>

Douglas E. Onsi ([\*\*\*])

Will McEvoy ([\*\*\*])

<u>The Agent</u>

Sameer Vasudev ([\*\*\*])

With copies to:

[\*\*\*]

**Exhibit 7(l)**

**Form of Representation Date Certificate Pursuant to Section 7(l)**

The undersigned, the duly qualified and elected [Secretary], of Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.), a Delaware corporation (the "<u>Company</u>"), does hereby certify in such capacity and on behalf of the Company, pursuant to <u>Section 7(l)</u> of the Sales Agreement, dated November 12, 2025 (the "<u>Sales Agreement</u>"), between the Company and Cantor Fitzgerald & Co., that to the best of the knowledge of the undersigned:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The representations and warranties of the Company in <u>Section 6</u> of the Sales Agreement (A) to the extent such representations and warranties are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Effect, are true and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date, and (B) to the extent such representations and warranties are not subject to any qualifications or exceptions, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date; *provided*, *however*, that in the case of clauses (A) and (B) such representations and warranties also shall be qualified by the disclosure included or incorporated by reference in the Registration Statement and Prospectus; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement at or prior to the date hereof.

Capitalized terms used herein without definition shall have the meanings given to such terms in the Sales Agreement.

---

| | |
|:---|:---|
|  | CYPHERPUNK TECHNOLOGIES INC. (F/K/A LEAP THERAPEUTICS, INC.) |
|  | By: |
|  | Name: |
|  | Title: |
| Date: [·] |  |

---

**<u>Exhibit 21</u>**

**Permitted Free Writing Prospectus**

None.

## Exhibit 5.1

**EXHIBIT 5.1**

November 12, 2025

Cypherpunk Technologies Inc.

47 Thorndike Street, Suite B1-1

Cambridge, MA 02141

Re: <u>Cypherpunk Technologies Inc. – Registration Statement on Form S-3 (File No. 333-278015)</u>

Ladies and Gentlemen:

We have acted as counsel to Cypherpunk Technologies Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the issuance and sale by the Company from time to time of shares of the Company's common stock, par value $0.001 per share, having an aggregate offering price of up to $200 million (the "<u>Placement Shares</u>"), pursuant to the Controlled Equity Offering Sales Agreement, dated November 12, 2025, by and between the Company and Cantor Fitzgerald & Co, as principal and/or sales agent (the "<u>Sales Agreement</u>").

In connection with this opinion letter, we have examined (i) the Registration Statement on Form S-3 (File No. 333-278015) (the "<u>Registration Statement</u>"), filed with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Act</u>"), on March 18, 2024, (ii) the accompanying base prospectus dated May 9, 2024 (the "<u>Base Prospectus</u>"), (iii) the prospectus supplement, dated November 12, 2025 (the "<u>Prospectus Supplement</u>" and together with the Base Prospectus, the "<u>Prospectus</u>"), filed with the Commission pursuant to Rule 424(b) under the Act, (iv) the Sales Agreement, (v) originals, or copies certified or otherwise identified to our satisfaction, of the Fourth Amended and Restated Certificate of Incorporation, as amended, and the Amended and Restated Bylaws of the Company, and (vi) such other documents, records and other instruments as we have deemed appropriate for purposes of the opinion set forth herein.

We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals of all documents submitted to us as copies.

Based upon the foregoing, we are of the opinion that the Placement Shares have been duly authorized by the Company and, when issued and sold by the Company and delivered by the Company against receipt of the purchase price therefor, in the manner contemplated by the Sales Agreement, will be validly issued, fully paid and non-assessable.

The opinions expressed herein are limited to Delaware General Corporation Law.

We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption "Legal Matters" in the prospectus included in the Registration Statement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Morgan, Lewis & Bockius LLP |

---